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Abstract 
Patricia A. Miguez 
Biglycan Modulation of Bone Morphogenetic Protein-2 Functions                                 
(Under the direction of Professor Mitsuo Yamauchi) 
 
Biglycan (BGN) is a proteoglycan found in high abundance in mineralized tissues. Study of 
its functions has unveiled roles in collagen organization (i.e. type VI), osteoblast 
differentiation, matrix mineralization, inflammatory processes, etc. Recently, we have 
reported that BGN promotion of osteoblast differentiation is due in part to its ability to 
positively modulate bone morphogenetic protein (BMP) functions. In the studies that follow, 
we (1) investigated the role of glycosaminoglycans (GAGs) of BGN on BGN-assisted BMP-
2 function in vitro by utilizing a C2C12 cell system and in vivo by using a critical-sized 
mandible defect model in the Sprague-Dawley rat; (2) characterized by microcomputed 
tomography and histology the newly formed bone (NFB) in BGN-assisted BMP-2-induced 
osteogenesis; and (3) investigated which domain of the core protein of BGN is most effective 
in promoting BMP-2 function in vitro and applied it in vivo. We found that BGN devoid of 
GAGs is most effective in assisting BMP function in vitro and in vivo and that this positive 
modulation in vitro occurs through increased phosphorylation of Smad 1/5/8. In the animal 
model, rats treated with a low dose of BMP-2 in conjunction with appropriate dose of BGN 
formed a less porous and more mature type of bone than a high dose of BMP-2 alone. High 
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dose BMP-2 formed an ectopic type of NFB and presented characteristics of a high turnover 
bone as per presence of osteoclast-like cells and yellow/orange picrosirius red staining. The 
BMP-2 and BMP-2 + BGN rats showed strong β-catenin immunoreactivity at 2 weeks post-
surgery. The rats that did not form significant amounts of bone did not show this pattern of 
staining. Finally, the effector domain of the core protein appears to reside between the N 
terminus and leucine rich repeat (LRR) 6, possibly in the LRR1~3. LRR1~3 was as effective 
as BGN full core protein in assisting BMP-2-induced osteogenesis in vivo. We conclude that 
the use of BGN or its effective domain combined with low concentrations of BMP-2 may be 
a more predictable, controllable and cost-effective approach than the use of high dose BMP-
2. 
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Chapter 1 
Review of Literature 
 
1.1. Bone  
Bone is characterized as a mineralized connective tissue built to provide support to 
the body, structure for muscle attachment, calcium and phosphate storage, site for 
hematopoiesis and generate cells involved in bone homeostasis. Bone is composed of cells, 
an inorganic matrix of hydroxyapatite (HA) minerals and an organic matrix of collagenous 
and non-collagenous proteins. The specific cells that are part of bone matrix are the 
osteoblasts (the bone forming cells on the surface of bone), the osteocytes (the bone cells 
embedded in bone lacunaes that sense mechanical loading) and the osteoclasts (the bone 
resorbing cells). The mineral phase of bone and other mineralized tissues like dentin and 
cementum provides stiffness while the organic phase mainly represented by collagen fibers 
provide ductility therefore preventing fracture. Type I fibrillar collagen is the major protein 
of the extracellular matrix (approximately 90%) in bone by weight and it serves as a spatial 
regulator by defining the space for mineral deposition and growth. Mineral is believed to be 
deposited initially within the fibrils and later between and around them. The amorphous 
calcium phosphate later matures into HA (Ca10(PO4)6(OH)2)/HAP) [1].  The complete 
process of biomineralization is highly ordered and tightly regulated by not only collagen 
deposition and assembly per se but by enzymes and other non-collagenous proteins. The non-
collagenous proteins in bone account for 10 to 15% of the total bone protein content and 
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Fig 1.1. Phylogenetic analysis and chromosomal organization of various human SLRP classes. The color-
coded dendrogram (left) shows the presence of five distinct families of SLRP and related LRR proteins. The 
consensus for the N-terminal Cys-rich cluster is also shown. The chromosomal arrangement of the various 
SLRP genes is shown in a telomeric orientation (right). Transcriptional direction is shown by the arrows above 
the color-coded boxes. ©Figure and legend reprinted with permission from American Society for Biochemistry 
and Molecular Biology. Schaefer L and Iozzo RV. Biological functions of the small leucine-rich proteoglycans: 
from genetics to signal transduction. Journal of Biological Chemistry 2008 August 1; 283 (31): 21305-21309. 
include glycosaminoglycan (GAG)-containing molecules called proteoglycans (PG) 
(polypeptide chain core with short N-linked oligosaccharides and large O-linked 
disaccharides), glycoproteins (polypeptide chain core with short N-linked oligosaccharides), 
phosphoproteins and gama-carboxy glutamic acid-containing molecules [2]. The main non-
collagenous proteins in bone are PGs of the small leucine rich family of proteoglycans 
(SLRPs) [3]. 
PGs are generally characterized as a collection of macromolecules that surround the 
cell membrane as well as provide a substrate for them to attach. They are composed of a core 
of polypeptide chains with one or more unbranched covalently bound GAG chains. The large 
structural diversity of proteoglycans gives rise to a wide variety of biological functions. Both 
core proteins and GAG chains have been shown to mediate these functions. They  have been 
involved in maintaining the transparency of the eyes, the tensile strength of skin and tendon, 
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Fig 1.2. Secondary structure, disulfide topology, and sequence conservation in the N-terminal capping motifs 
of SLRPs: (a) ribbon diagram of the N-terminal cap from the decorin crystal structure: (b) ribbon diagram of 
the disulfide N-terminal capping for nyctalopin (also a LRR proteoglycan), showing the predicted topology of 
the three disulfide bonds; (c) structure-based sequence alignment for the N-terminal motifs of all SLRPSs. 
Yellow, conserved residues; green, partially conserved residues; cyan, partially conserved Pro residues 
indicative of polyproline II conformation; magenta, polar residues occupying hallmark LRR hydrophobic 
sites. Cysteine residues are shown in white text over red background and conserved disulfide bonds are shown 
as red solid lines. Including a predicted additional disulfide bond in nyctalopin that is shown as a red dashed 
line. © Figure and legend reprinted with permission from Elsevier. McEwan et al., Structural correlations in 
the family of small leucine-rich repeat proteins and proteoglycans. Journal of Structural Biology 2006 
August; 155(2): 294-305. 
 
the viscoelasticity of blood vessels, the compressive properties of cartilage and the 
mineralization of teeth and bones [4]. 
1.2. Small leucine rich proteoglycans (SLRPs) 
SLRPs were first identified as small PGs in bone [5] and the family has expanded 
considerably from the first two SLPRs in one family (DCN and BGN) to the present 
seventeen SLRPs in five families (Fig 1.1). In their structure they have N-terminal cysteine 
(Cys) clusters with defined spacing, an ear-repeat at the C-terminal [6] and at least one GAG 
attached [4, 7]. They are usually small, below 150 kDa including their GAGs. The N-
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terminal cluster typically contains four Cys and the amino acids that space them have been 
used as a way to subdivide the SLRP family. The fourth and last Cys of the N-terminal is 
embedded in the leucine-reach repeat (LRR)-1. Thus, this N-terminal capping is not a 
separate domain from the LRR-1 (Fig 1.2). Most of the data on SLRPs arise from the 
extensive research on the Class I SLRP DCN. One study shows the importance of the N-
terminal Cys as the lack of binding of DCN to collagen under reducing conditions highlights 
the hypothesis that the amino terminal of SLRPs is important for its function [6, 8].  It has 
been speculated that this capping protects the hydrophobic core of the first LRR and 
therefore LRRs would not fold correctly and would not function properly in the absence of 
the disulfide bonds. The ear repeat refers to the C-terminal capping involving the last LRR in 
SLPRs. All class I, II, III and extracellular matrix protein 2 (ECM2) share the same N and C-
terminal capping in their LRR domains [9]. 
In general, the family of SLRPs is organized according to the protein core and 
genomic homology, chromosome location and Cys regions into 5 subclasses (Fig 1.1). Also 
their genes (with the exception of BGN) are organized in three chromosomal clusters [10], 
suggesting close evolutionary relationships as predicted in Fig. 1. 1.  
SLRPs are reported to play a role in extra cellular matrix (ECM) development and 
maintenance as well as regeneration.  Mice lacking one or two SLRPs have shown the 
importance of these PGs on bone formation and maintenance among other physiological 
development steps [11-15]. The phenotype of these mice is mostly due to affected collagen 
fibrillogenesis leading to skin fragility (with lack of SLRP DCN)[14] or osteoporosis and 
spontaneous aortic dissection (with lack of SLRP BGN) [11].  
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Fig 1.3. Possible ligand-binding scenarios for 
dimeric SLRPs: dimers may bind two molecules of 
a ligand as in (a), or one dimeric ligand as in (b);  
alternatively the dimers might disassemble and use 
their concave surfaces for binding ligands with 1:1 
stoichiometry as in (c), or with more complicated 
stoichiometries as in (d). The N-linked 
oligosaccharides accumulate on one side of the 
decorin dimer (c), leaving the surface on the other 
side mainly available for possible protein-protein 
interactions. © Figure and legend reprinted with 
permission from Elsevier. McEwan et al., Structural 
correlations in the family of small leucine-rich 
repeat proteins and proteoglycans. Journal of 
Structural Biology 2006 August; 155(2): 294-305. 
 
1.2.1. SLRP-ligand binding 
Several SLRPs have been shown to interact with different types of collagen, both fibrillar 
and non-fibrillar, and to recognize different collagen sites [16-18]. DCN and asporin (ASPN) 
bind to same site of collagen type I and therefore compete. DCN has a negative effect on 
collagen mineralization and it has been suggested that the polyaspartate acid in ASPN also 
directly regulates mineralization [19].  
More recently, special attention has been 
given to SLRPs binding to growth factors of the 
transforming growth factor (TGF)-β family. The 
binding of DCN and BGN to TGF-β1, 2 and 3 
and TGF-β family members bone morphogenetic 
proteins (BMPs) led to extrapolating the 
functions of SLRPs not only on ECM assembly 
but also cell signaling [20]. Binding studies with 
ASPN also show its specific binding to TGF-β1 
and influence on expression of different 
osteogenic markers highlighting the importance 
of these Class I SLPRs on ECM osteogenesis 
and mineralization [20]. 
Some SLRPs have also been reported to 
trigger signaling pathways independently of 
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Fig 1.4.The structural domains of SLPRs. The core protein of decorin, 
biglycan, fibromodulin or lumican is depicted with two disulphide 
bonded domains flanking ten leucine-rich repeat (LRR) domains. Each 
LRR domain is composed of the sequence LXXLXLXXNXL, where L 
is predominantly leucine but may also be I, V, A, M, F or Y, and X 
may be any amino acid. In the case of decorin or biglycan, one or two  
chondroitin/dermatan sulphate (DS) chains, respectively, reside in the 
amino terminal region. In the case of fibromodulin and lumican, one to 
four keratan sulphate chains (KS) may reside between the LRR. © 
Reprinted figure and legend from open access journal of AO 
foundation. Roughley PJ. The structure and function of cartilage 
proteoglycans. European Cells and Materials 2006 November 30; 12: 
92-101. 
 
TGF-β [12, 21-23]. DCN and most recently BGN seem to be very promiscuous molecules, 
with many reported interactions with various receptors, cell secreted molecules and ECM 
components [16, 24-30]. Through these interactions, SLRPs influence a variety of signaling 
pathways including Wnt, mothers against decapentaplegic (Smad) and mitogen-activated 
protein kinase (MAPK) [29, 31-33].  
Despite all the data, especially for DCN, the molecular details and the stoichiometries 
of the interactions between SLRPs and their ligands remain a mystery. It has been generally 
assumed that all SLRPs have a horseshoe shape and that the concave side of the horseshoe 
contains the binding sites. However, it is now known that DCN and other SLRPs form 
extremely stable dimers in solution and that those dimers assemble through the concave side 
of the monomers. This warrants rethinking of the assumptions that only the concave area 
serves as a binding site [6]. In Fig 1.3 several scenarios are illustrated. Dimeric SLRPs may 
function as units binding ligands with a 2:2 stoichiometry with a twofold symmetry (Fig. 
1.3a). Dimerization of SLRPs may 
facilitate their interaction with 
other dimmers or oligomers such 
as TGF-β and epidermal growth 
factor (EGF) receptor (Fig. 1.3b). 
Conceivably, dimeric SLRPs 
might also dissociate to interact 
with some partners as monomers 
(Fig. 3c and d).  
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1.3. Biglycan 
BGN, a member of class I molecules in the SLRP family, is one of the major non-
collagenous proteins in mineralized tissues and was originally identified in the mineral-
associated compartment of bone [5]. It consists of about 45 kDa core protein made of 10-12 
LRRs that are about 25 amino acids long [34]. BGN has a signal sequence, a propetide, two 
GAG chains attached to its amino terminus, a Cys loop flanking the N-terminal side of the 
central LRR region that makes up over 66% of the core protein, and a final Cys loop at the 
carboxy-terminus [35] (Fig 1.4) . BGN is first synthesized as a pro-form containing 20 
residues of N propeptide (human), which will subsequently be removed in most connective 
tissues. The propeptide containing form is more prevalent in articular cartilage. The function 
of this propetide is not fully understood but the proteinase responsible for the cleavage has 
been identified as BMP-1. The sites where BMP-1 processes BGN, M(M/L)N-DEE, are 
conserved in various species [36]. BGN can undergo further proteolytic cleavage to remove 
the N-terminal peptide containing GAG chains, resulting also in a non-PG form of the 
molecule [37].  
The BGN gene is located on the X chromosome, the Xq28 region in human [38] and 
at a locus 50-100 kb distal to the DXHSS52 locus in the murine counterpart [39]. Human and 
murine BGN consist of eight exons and spans over 8 kb for the former and 9.5 kb for the 
latter. The murine BGN is larger than human due to the intron present between exon 1 and 2. 
As in other members of the SLRPs its core protein is proposed to have a horseshoe structure 
which can facilitate protein-protein interaction (Figs 1.3). BGN has been localized to several 
regions including cartilage, periosteum and skeletal myofibers and keratinocytes [40]. It has 
been identified in the ECM space, as a nucleator for mineral deposition [41], or at the cell 
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Fig 1.5. Radiological analysis of bones from 
Bgn+/0 and Bgn−/0 mice. a-c, Radiographs of 
femora from wild-type (+/0) and mutant (-/0) mice 
at the age of three (a), six (b) and nine (c) months. 
Note the progressive decrease in trabecular bone 
mass (*) with age in the mutant compared with 
wild-type mice. d,e, Details of high resolution 
microradiographs of six-month-old animals. Note 
that the trabecular bone is reduced and extends 
over a shorter distance below the growth plate in 
the mutant bone (e). Also note that the angle 
between the femoral neck and the great trochanter 
(arrows) is wider in the mutant bone, a difference 
in shape that was consistently observed (d). © 
Figure and legend reprinted with permission from 
Nature. Xu T, et al. Targeted disruption of the 
biglycan gene leads to an osteoporosis-like 
phenotype in mice. Nature Genetics 1998; 20: 78-
82.  
surface indicating possible regulatory role in cell activities [40]. As a mineral nucleator, 
BGN and DCN were both found to bind to HAP in a HAP coated affinity column. In 
addition, DS-DCN and DS-BGN obtained from skin and articular cartilage where analyzed in 
a gelatin gel diffusion system in which apatite formation occurs in the absence of cells in a 3-
5 day period. CS-PGs and DS-BGN promoted the most crystal growth [41]. This data 
supported the notion that BGN plays a more significant role than DCN in mineralization. 
In some instances, BGN has been described as carrying only one GAG chain [37, 42-
44]. In a study of mutation of Serine (Ser) 
residues of BGN, it was shown that the first site 
Ser 42 is important for the second site Ser 47 to 
be glycanated. When Ser 42 is mutated, only a 
small portion of BGN is glycanated. In addition, 
the authors found that BGN may carry heparan 
sulfate (HS) GAGs chains as well as sulfated N-
linked oligosaccharides [45].  The specific clear 
functions of DS-, CS- and HS-BGN have not 
been determined so far. 
 
1.3.1. Biglycan is a positive modulator of 
osteoblast function 
In order to evaluate the function of full protein 
BGN in connective tissues, BGN-knockout mice 
were generated using gene targeting and 
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homologous recombination [11]. This study and others using the same model have found that 
BGN deficiency caused decreased bone mass, irregular collagen fibrillogenesis and thin, 
disorganized dermis  [11, 46-48](Fig 1.5).  It was proposed that BGN levels can control the 
level of cell proliferation leading to decreased amount of osteoblast progenitors [46]. It was 
also proposed that these mice had compromised ability to make new bone because of a 
reduced response of bone marrow stromal cells to TGF-β [49]. The same group further 
reported that BGN together with DCN may control the fate of bone marrow stromal cells, 
thus, the lack of these SLRPs could cause the reduced number of osteoprogenitor cells [13, 
50].  
When BGN deficient osteoblasts isolated from the neonatal calvaria were determined 
having less response to BMP-4 stimulation an attempt to restore this response was pursued. 
The poor response to BMP-4 stimulation was restored when the BGN-deficient cells were 
infected with BGN-expressing adenovirus. The authors then concluded that osteoblasts 
lacking BGN displayed a defect in differentiation due to reduced BMP-4 binding, followed 
by lower BMP-4 sensitivity, resulting in less BMP-4 signal transduction and decreased 
expression of core binding factor α1 (Cbfa1), an essential transcription factor for osteoblast 
differentiation [49]. This could partially explain the cause of age-dependent osteoporotic 
phenotype observed in BGN-deficient.  The poor responsiveness of the clones to BMP-4 also 
indicates its potential involvement of BGN in BMP function. 
On the other hand, in studies addressing the regulation of BMP-4 signaling pathways 
during embryonic development, BGN has been shown to bind BMP-4 and accelerate the 
inhibitory effects of BMP antagonist molecules [chordin and Tsg (Twisted gastrulation)] on 
BMP-4 activity by increasing the binding of BMP-4 to chordin and improving the efficiency 
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of chordin-Tsg complexes to inactivate BMP-4 [51]. Later, in Xenopus embryos, the 
microinjection of biglycan mRNA inhibited BMP-4 activity and influenced embryonic 
development in a chordin-dependent manner. The lack of BGN in bone vs. other tissues (i.e. 
tendon) promotes different behaviors of cells which could indicate a tissue-specific function 
of BGN potentially influenced by different players in BMP signaling, e.g. competitive 
binding of BMP-2 and BMP-4 to BGN and other SLRPs.  
After the initial characterization of BGN deficient mice and the initial findings of the 
functional relationship between BGN and BMPs in controlling skeletal differentiation, our 
laboratory continued to unveil the mechanism of BGN-assisted BMP function.  In 
Parisuthiman et al., 2005 [52], we reported that in early stages of cell culture the expression 
of Cbfa1 and osterix (Osx), as well as matrix proteins [i.e. type I collagen, bone sialoprotein 
(Bsp)] were significantly upregulated in pre-osteoblastic MC3T3-E1 cells overexpressing 
Bgn (Sense, S) but downregulated in clones underexpressing (anti-sense, AS) Bgn. 
Mineralization was significantly accelerated in S clones but impaired in AS clones in vitro 
and in vivo. These phenotypes of S and AS clones indicate that BGN is a positive modulator 
of osteoblast differentiation and promoter of mineralization (Fig 1.6). BGN is the first known 
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Fig 1.6. In vitro (A) and in vivo (B) mineralization assay. (A) Mineralized nodules were formed earlier and to a greater 
extent in S clones compared to those of controls, while no nodules were observed in AS clones up to day 28. (B) H&E 
stained sections of transplants show bone-like matrices (B) including osteocytes (arrowheads) (left panel) on the surface 
of HA/TCP carrier (HA). The percentage of bone-like matrices is shown as B/T+SD and B/T-HA+SD (right panel). The 
bone-like matrix areas are significantly greater in S clones while they are markedly smaller in AS clones than those of 
controls. a =p< 0.005 vs. controls. Bar=500 μm. © Figure reprinted with permission from John Wiley and Sons. 
Parisuthiman D et al. Biglycan modulates osteoblast differentiation and matrix mineralization. JBMR 2005(20): 1878-
1886.  
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agonist of BMP function and has just recently been attributed such function. In comparison 
to the extensive studies on the BMP-antagonists little is known about the positive matrix 
modulators of BMPs. A study by Xiao and coworkers has indicated that matrix accumulation 
is necessary for endogenously or exogenously added BMPs to be fully functional in a 
MC3T3-E1 cell culture system [53] . The ECM is composed of heterogeneous molecules, 
including SLRPs thus this may support the idea that those SLRPs (i.e. BGN) in ECM are 
needed for BMP to function.   
Besides the studies with endogenous increase or decrease in BGN production, we 
further evaluated the effect of exogenous BGN addition on osteoblast differentiation. In 
Mochida et al., 2006 [28], it was reported that exogenously added recombinant BGN (tagged 
with glutathione-S-transferase, GST) is able to significantly promote BMP-2 function in 
C2C12 osteoblasts. GST tag alone was found not to cause any enhancement of BMP 
function. It was found that recombinant BGN induced earlier and stronger Smad 1/5/8 
pathway activation. This activation was also sustained for a longer period of time in BGN + 
BMP-2 compared to BMP-2 alone. More recently, the underlying pathways of osteoblast 
differentiation through exogenously added BGN was also studied in MC3T3-E1. BGN was 
found to activate not only Smad but also ERK signaling pathways in these pre-osteoblasts. In 
this venue, GAGs were found to play an essential role as deglycanated BGN did not promote 
ERK signaling in these cells [33]. 
 
1.3.2. Biglycan binding partners  
BGN has previously been considered as a non fibrillar collagen-binding molecule [54]. 
However, by employing immunogold labeling technique and immunoprecipitation 
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(IP)/Western blot (WB) analysis, the binding between recombinant radiolabeled BGN or in 
vitro native BGN and reconstituted type I collagen fibrils has been shown [18]. The binding 
of the core protein of BGN to collagen is not as strong as of DCN. However, when full 
protein DCN and BGN (with GAGs) compete, the dissociation constant among them is 
similar. In other words, BGN with GAGs binds much more strongly to collagen than without 
them [55, 56].  
Besides type I collagen, BGN has also been shown to bind to collagens type II, III, V 
and VI [17]. In the case of type VI collagen, BGN acts as an organizer for the formation of 
hexagonal-like network, which resemble tissue structures [57]. Without GAGs BGN is not 
able to bind collagen type VI or has its binding ability to collagen II significantly reduced 
[17]. 
But given the preferential localization of BGN to pericellular space, ECM collagens 
seem not to be the favored binding partners of BGN.  Reports of DCN binding to cell surface 
and correlating with levels of growth factors was first described in the late eighties [58]. 
They found a negative regulation of TGF-β levels by DCN. Later, Hildebrand et al., 1994 
[20] found that bacteria generated DCN, BGN and fibromodulin bound TGF-β1, -2 and -3 in 
a dose dependent manner. They also found that removal of GAGs was most beneficial when 
binding to TGF-β1. 
The DS GAGs of SLRPs, like in BGN, have also been reported to bind fibroblast 
growth factor-2 (FGF-2) during the wound healing process [59]. Speculatively, proteolytic 
scission may be accompanied by dissociation of the BGN (proposed as a dimer form), 
leaving a truncated, monomeric PG free to diffuse to its target cells. These latter points are 
speculative but, as noted by the authors [60], murine enzyme HtrA1 rapidly degrades the 
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BGN core protein [61]; and the glycanated portion interacts with FGF-2 and its receptor 
while the chopped part is diffused or stays bound to collagen in ECM [62]. 
Mochida et al., 2006 [28] have also reported that BGN binds BMP-2, -4 and -6 in a 
cell culture system by IP-WB analysis. Interestingly, when direct binding assay by GST pull 
down was performed (BGN was tagged with GST), only BMP-2 showed significant binding 
to BGN, suggesting that the binding of BGN to BMP-2 is direct not requiring other 
molecules. In addition, they found that BGN specifically binds to the type I receptor BMP 
receptor IB (BMPRIB, also called activin-like kinase-6 or ALK-6). The type I receptors 
primarily determine the BMP signaling pathway and ALK6 is essential for osteoblast 
differentiation and bone formation. Other receptors like ALK2 and ALK5 and type II 
receptor BMPRII also showed detectable binding to BGN in cell culture system. In BMP-2 
signaling, mainly ALK3 or ALK6 in combination with BMPRII have been described as the 
oligomerization pattern for BMP-2 function [63]. 
Aside from growth factor receptors, there is growing evidence that BGN may convey 
inflammatory processes through pathogen recognizing receptors. Mice lacking BGN survive 
lipopolisaccharide (LPS) challenges that otherwise would kill them. Addition of LPS induces 
secretion of interleukin (IL)-1 and -6 equally in cells with and without BGN, but addition of 
IL-1 to wild type macrophages increases BGN mRNA and protein, increasing TNF-α 
production. BGN alone also activates the MAP kinase pathways of ERK and p38 in 
macrophages. These events were found to be likely through toll like receptors (TLR)-4, 
although there was also BGN binding to TLR-2 which led to increased TNF-α. Interestingly, 
BGN devoid of GAGs, is not able to cause such response [29, 32]. It is clear that the effect of 
GAGs of BGN on its functions needs to be further investigated.    
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1.3.3. Glycosaminoglycans (GAGs) of BGN 
The LRRs of the protein cores, which are considered to be particularly relevant for protein-
protein interactions, have established SLRPs as important regulators of various biological 
processes [14, 15, 46, 64-66]. The involvement of GAG chains, however, has not been 
investigated in greater detail.   
GAGs are long unbranched polysaccharides consisting of repeating disaccharide unit. 
This unit consists of an N-acetyl–hexosamine [e.g. galactosamine (GalN) or glucosamine 
(GlcN)] and a hexose or hexuronic acid [e.g. galactose (Gal) or glucuronic acid (GlcA) or 
iduronic acid (IdoA)].  Either or both of each may be sulfated. The combination of the sulfate 
group and the carboxylate groups gives them a very high density negative charge. BGN was 
named due to two CS/DS GAGs attached to its N-terminus. In mineralized tissues, BGN has 
being predominantly substituted with the GAG composed of CS at the N-terminus while in 
soft tissues, predominantly carry DS [34]. DS is distinguished from CS by the presence of 
IdoA. CS and DS are attached to the core protein at their reducing end through a 
tetrasaccharide region consisting of GlcA-Gal-Gal-Xyl with the xylose (Xyl) glycosydically 
linked to the hydroxyl group of Ser adjacent to a glycine (Gly) residue in the protein core.  
The first sugar of the GAG chain (linked to the Gal) is always GlcA, but is considered to be 
part of the linkage oligosaccharide. The biosynthesis of all PG, except the keratan sulfate 
(KS) portions of cartilage and cornea, consist of: (1) synthesis of the core protein; (2) 
xylosylation of specific Ser moieties of the core protein; (3) addition of two Gal residues to 
the Xyl; (4) completion of a common tetrasaccharide linkage region by addition of a GlcA 
residue; (5) addition of an GalN or GlcN residue to initiate the chondroitin/dermatan or 
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heparin GAG, respectively; (6) repeat addition of hexosamine residues alternating with GlcA 
residues to form the large heteropolymer GAG chains; and (7) modification of these GAGs 
by variable N-deacetylation/N-sulfation, and/or O-sulfation, and variable epimerization of 
GlcA to IdoA. Each of the GAGs involves several enzymes that have been cloned from 
vertebrates and other sources as Drosophila, C. elegans and zebra fish. The first steps of the 
synthesis of GAG chains of CS/DS and HS share a common pathway involving xylosyl 
transferase (Xylt1, Xylt2), β4-galactosyltransferase (β4galt7), β3-galactosyltransferase 
(β3galt6), β3-glucuronosyltransferase (β3gat1, β3gat2, β3gat3). CS/DS linkage region 
biosynthesis and chain extension require two additional enzymes, β4-GalNAc transferase 
(GalNAct2), and chondroitin synthase (Chsy1, Chsy2, Chsy3-like), which has both β 
3GlcAcT and β4GalNAcT activities required to form the repeating disaccharide unit. Lastly, 
several enzymes are involved in the modification of the CS/DS GAG repeating unit (5 
enzymes) that add sulfate to GlcA/IdoA (2S) or GalNAc (4S and/or 6S) [67]. 
The role of the GAG chains has not been explored in the interaction between BGN 
and BMPs. Previously, studies on the role of GAGs of PGs that carry HS have proposed that 
they play an important role in signal transduction through interaction with growth factors and 
chemokines and that the negative charge of GAGs are responsible for attracting these basic 
proteins [68]. However, besides charge, the position of those GAGs in the PG may also affect 
the binding of molecules to the core protein per se [69]. From Mochida’s study, it is clear 
that BMP-2 binds to the core protein of BGN [28]. But it is not known what type of effect the 
GAGs would have on BGN-BMP binding and consequently BMP signaling. We could 
speculate that the GAG chains may modulate the interaction of BGN with BMP and possibly 
its receptor.  
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Despite growing recognition of the importance of GAGs in many physiological 
processes, a detailed understanding of their structure-function relationship has been lacking. 
Part of this is because extensive amount of these glycosides are needed to study GAG-protein 
interaction and generation of GAGs by overexpression of GAG-synthesizing enzymes is 
difficult due to the involvement of numerous enzymes for their biosynthesis as described 
above. Despite the difficulties, several studies have been able to prove through affinity 
chromatography, electrophoretic mobility shift assays and GAG removal by enzymes, i.e. 
chondroitinase ABC (C-ABC), that GAG components of PGs are coregulators of many 
growth factors. HS-PGs play crucial roles in regulating key developmental signaling 
pathways such as the Wnt, Hedgehog, TGF- β and FGF [4, 70]. In these studies, mutations in 
the enzymes responsible for the biosynthesis of GAG chains have unveiled the importance of 
PGs in development. But other than HS, the functions of CS/DS PGs have not been well 
studied in relationship to growth factor interaction. BGN carries most often two CS/DS 
chains that are linked to Ser 42 and 47 of the core protein. However, there have been reports 
of ~30% of the core protein being substituted with a single chain only [42, 43]. In addition, 
proteolytic processing of BGN may generate non-glycanated forms of the molecule [37, 44]  
as also described earlier for Htra1 [61]. Alterations to PG levels and/or GAGs have been 
reported in the literature in osteogenesis imperfecta [71, 72] , mucopolysaccharidosis [73], 
progeroid form of Ehler-Danlos syndrome [74, 75]  and aging [72]. BGN has been shown to 
be decreased and have altered GAG structure in osteogenesis imperfecta and during aging, 
conditions that show osteopenic phenotype. The double knock out of DCN and BGN mimic a 
rare disease (OIM#130070) which is characterized by a defect in galactosyltransferase I 
activity which is responsible for GAG formation and the outcome is production of small PGs 
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devoid of GAG chains. These data suggest that the GAG chains may have important 
functions in bone. They also suggest a possible role for the GAGs of BGN in bone formation 
and maintenance. Considering the physicochemical properties of GAGs and recent studies 
demonstrating their involvement in PG functions, the GAG component of BGN could also 
affect the interaction of BGN with BMPs or their receptors consequently the BMP signaling.  
The distribution of disaccharides along the polypeptide chains of SLRPs like DCN 
and BGN have been proposed. The disposition of monomers in the DCN dimer directs the 
long GAG chains away from the dimer interface [36]. This would allow the simultaneous use 
of the GAG or O-linked sugar chains and the protein cores for functional interactions. 
Additionally, the protein core of DCN contains three N-linked oligosaccharides that are all 
positioned on one side of the DCN dimer (glycan-rich surface), opposite to the ear 
projections (see Fig. 1.3e)[76]. This glycan-rich surface would not be used in protein–protein 
interactions. However, depending on the site where growth factors like BMP or its receptors 
would interact with BGN, GAGs may work as a barrier for growth factor binding.  
 
1.3.4. Biglycan core protein  
Besides the determination of the role of GAGs on BGN functions, the determination of the 
role of the core protein or its domains is of interest. The sequence, folds and turns of the 
polypeptide chain could presumably influence function. DCN and BGN have very similar 
secondary and tertiary structures although their sequence homology is quite different. Take 
for instance the structure of the first LRR that is always connected to the N-terminal 
sequence by a disulfide bond and said to be important for stability of the LRRs. It is about 68 
amino acids long in both proteins but only have two 7 amino acid long sequences that are 
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identical with other random similar amino acids. The remaining LRRs follow the same 
pattern, thus with very limited homology. Yet again, the full protein DCN and BGN 
functions have started to be unveiled and they seem to be quite different and even opposites 
in some circumstances. The peculiarities in the sequences and/or structures of those proteins 
should hold the secret to their different functions as in conformation (horseshoe dimmers) 
they are very similar. 
1.4.  Bone morphogenetic proteins  
BMPs were originally identified from extracts of bone matrix after an orthopedic surgeon 
and researcher, Urist,  found that demineralized bone matrix could induce heterotopic bone 
formation in a rodent model [77]. Since then, more than 20 related proteins with BMP 
sequences and activities have been sequenced and cloned [78, 79]. They have been either 
purified from bone or generated by recombinant DNA technology and shown to induce 
endochondral or intramembranous bone formation depending on the anatomical site in which 
they have been administered. BMPs are members of TGF-β superfamily.  The superfamily 
consists of proteins that have a highly conserved seven Cys domain at the carboxy-terminal 
region. This super family of proteins includes five isoforms of TGF–β (1 through 5), the 
BMPs, growth differentiation factors (GDF), activins, inhibins and Mullerian inhibiting 
substance [80]. They are dimeric molecules with two polypeptide chains held together by a 
single disulfide bond, secreted as precursors, processed to release mature, active proteins 
which have a molecular weight of 20-30 kDa retaining the critical seven Cys residues [81] 
(Fig 1.7). The superfamily has impact on a wide array of cellular activities including cell 
growth and differentiation as well as the synthesis of ECM. BMPs control many key steps in 
the development of organs (heart, kidney, reproductive organs, the vertebrate nervous system 
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Fig 1.7. The structure of the BMP-2−BRIA 
ectodomain complex. a, Side view with the 
membrane proximal side on the bottom and b, top 
view approximately along the twofold axis of the 
complex in a ribbon representation. The BMP 
monomers are colored gold and blue, the two 
BRIA ectodomain molecules are green. Secondary 
structure elements, chain termini and receptor 
loops 1 and 3 are labeled. The 'wrist' and the 
putative 'knuckle' epitopes on BMP-2 are 
highlighted. © Figure and legend printed with 
permission from Nature. Kirsch et al., Crystal 
structure of the BMP-2-BRIA ectodomain 
complex. Nature Structural Biology 2000 7: 492-
496.  
 
regulating cell fate, proliferation and differentiation) [82-84]. During embryonic 
development, BMPs mediate apoptosis and accumulated evidence indicates that BMPs play 
an important role in regulation of stem cell properties [85-87].  There is also evidence of the 
role of BMPs in oncogenesis/tumor suppression [88, 89].  
It is now clear that BMPs upregulate the 
expression of critical transcription factors, 
Cbfa1/runt-related transcription factor 2 (Runx2) 
[90, 91] and Osx [92, 93], and a number of matrix 
molecules genes such as type I collagen, alkaline 
phosphatase (Alp), osteocalcin and SLRPs, 
essential for osteoblast differentiation and matrix 
formation/mineralization [94-97]. Of BMP 
members, BMP-2, -4, -6 and -7 (the latter is also 
known as osteogenic protein-1) are known to be 
potent osteoinductive growth factors [98, 99] that 
induce osteogenic differentiation of pluripotent 
mesenchymal cell lines (such as C3H10T1/2) and 
promote the maturation of osteoblastic progenitor 
cells [100-102]. In the myogenic cell line C2C12, 
for instance, BMP-2 suppresses the expression of myogenic markers such as  Myo-D and 
myogenin, and stimulate the expression of genes involved in osteogenesis, such as Alp, 
parathyroid-hormone/parathyroid-hormone-related protein receptor, osteocalcin (Ocn), 
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Cbfa1/Runx2  and Osx, thus transdifferentiating from myogenic to osteogenic cell lineage 
[91, 93, 103]. 
BMP-2 has mostly received attention and most of the in vitro as well as human in 
vivo studies involve BMP-2.  Its approval for human use by the FDA occurred in 2002. 
Unfortunately, despite large amounts of BMP being used for human application especially 
for spine fusion procedures and more recently for maxillofacial grafting, a percentage of 
bone regeneration procedures is not completely successful. Clinical complications have been 
attributed to a hyper inflammatory response due to the high amount of BMP-2 delivered 
[104]. But little is known about the key players in BMP function and thus modulation rather 
than increasing its amount may be the answer to some of its clinical limitations. 
1.4.1. BMP antagonists and agonists 
The process of BMP signaling is highly controlled by numerous molecules at extracellular, 
cell surface and intracellular levels (Fig 1.8).  A well orchestrated and tight control of BMPs 
by these molecules at various levels is crucial for the normal cell functions. At the cell 
surface, a pseudo type I receptor, BAMBI, antagonizes the effects of BMPs by preventing the 
formation of active receptor complexes [105], while a co-receptor, DRAGON, potentiates 
BMP signaling by interacting with BMPs and receptors [106].  
At the intracellular level, BMP signaling is inhibited by several I (inhibitory)-Smads 
(Smad 6 and 7) that efficiently interact with activated type I receptors and compete with R 
(receptor-regulated)-Smads (Smads1, 5 and 8) for type I receptor interaction [107]. The 
signal is also inhibited by two closely related Smurf (Smad ubiquitination regulatory factors) 
1 and 2 that selectively degrade the activated type I receptor and Smad proteins [108, 109].  
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Fig 1.8. BMP Signal Transduction. Shown here is the canonical BMP–Smad signaling pathway. BMP agonists are 
post-transcriptionally cleaved and processed, and then form active dimers. Upon receptor binding, two type I and 
two type II receptors associate to form a hexameric receptor–agonist complex. On activation, type I receptors are 
trans-phosphorylated by type II receptors. Type I receptors, in turn, phosphorylate their R-Smads. Phosphorylated 
R-Smads form a complex with the co-Smad, Smad-4, translocating to the nucleus, and promoting transcription of 
target genes. In the presence of active BMP antagonists a ternary agonist–antagonist complex is formed in the 
extracellular space and receptor activation is prevented. Steps 1–6 mark both the intracellular and extracellular sites 
at which the signaling pathway can be modulated. Step 2 highlights the likelihood that regulation of BMP and 
BMP-antagonist expression by as yet undiscovered miRNA will probably be revealed in the near future. BMPR, 
BMP receptor; Smurf, Smad–ubiquitin regulatory factor . © Figure and legend reprinted with authorization of 
Elsevier. Walsh  et al. Extracellular BMP-antagonist regulation in development and disease: tied up the knots. 
Trends in Cell Biology 2010 March; 20(5): 244-256. 
 
In the extracellular space, antagonists are classified into three subgroups based on the 
size of the cystine-knot; Dan family (eight-membered ring), Tsg (nine-membered ring) and 
chordin/noggin (twelve-membered ring) [110-112]. These secreted polypeptides inhibit BMP 
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activity by binding BMPs, thus preventing BMPs binding to their specific cell receptors. 
Interestingly, the expression of some of these antagonists is induced by BMPs indicating a 
local feedback mechanism to maintain the balance between BMPs and inhibitors. 
BMP agonists have not been well defined. A recent attempt to agonize BMP function 
was through identification of a key residue on BMP-6 that conferred noggin resistance. 
Introduction of a Lysine (Lys) residue at the corresponding positions of BMP-2 and BMP-7 
allowed for molecular engineering of recombinant BMPs with increased resistance to noggin 
antagonism [113]. 
 
1.4.2. BMP receptors and downstream signaling 
BMPs bind to BMP receptors composed of two transmembrane serine/threonine (Thr) 
protein kinases, type-I and type-II (BMPR-I and II). They consist of a signal peptide, Cys-
rich extracellular domain, transmembrane region and Ser/Thr kinase domain [114]. The 
affinity of BMPR-I for BMPs is higher than that of BMPR-II  [115], thus, it is likely that 
BMPs bind BMPR-I initially and then recruit BMPR-II into the complex as demonstrated by 
Gilboa et al [63]. There have been also reports of pre-formed complexes of type I and II 
receptors prior to BMP binding [63]. Three type I receptors for BMPs have been 
characterized: activin receptor-like kinase-2 (ALK2), type IA and IB BMP receptors (BMPR-
IA/ALK3 and BMPR-IB/ALK6) [116, 117]. The various assembly modes can also lead to 
different pathways activation. The type II receptors are constitutively active and 
phosphorylate the Gly-Ser (GS) box of type I receptors. Then the activation of type I receptor 
kinases initiate phosphorylation of specific downstream components including the nuclear 
effector proteins, Smads, in chondroblasts and osteoblasts. The Smad pathway is the 
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canonical downstream event upon BMP-2-receptor coupling. These R-Smads 1, 5 and 8 are 
released from the receptors to form a hetero-oligomeric complex with a common mediator 
Smad (Co-Smad; Smad 4), which is capable of migrating into the nucleus to function as 
transcription factors to regulate specific BMP target genes in concert with several co-factors  
[107, 118] (Fig 1.8).  
The non-Smad pathways of ERK, p38 and Wnt have also been reported to be 
influenced by BMP [33, 53, 119, 120].   The activation of such pathways may occur via 
internal cellular cross-talks or different patterns of oligomerization mode of the receptors or 
interaction/stimulation of other molecules important for the activation of those pathways.  
Recently, Wnt signaling has been described as an important pathway in bone regeneration 
that is induced by BMP-2 and strongly present during fracture repair [121]. The mechanisms 
by which Wnt signaling is activated during repair are still largely unknown. Similarly, the 
mechanisms by which BMP-2 acts in in vivo bone regeneration are also largely unknown.  
The pattern of expression of those receptors is different from each other with ALK3 
being expressed throughout the tissues in the body during mouse development and in adult 
tissues, whereas ALK6 during mouse development is expressed in mesenchymal pre-
cartilage condensations and in chondrocytes and osteoblasts at adult stage [122, 123]. In our 
laboratory, we have found that ALK6 expression in MC3T3-E1 cells  peaks at 7 days  and is 
significantly reduced from then on (unpublished data). ALK6 has been shown to be essential 
for osteoblast differentiation and matrix mineralization by using truncated dominant-negative 
and constitutively active forms of ALK3 and 6 in a clonal osteoblast precursor cell line, 2T3 
[85]. When a truncated ALK6 targeted to osteoblasts using the type I collagen promoter was 
overexpressed in mice, the transgenic mice showed defective bone formation (bone mineral 
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density, bone volume, rate of bone formation) due to the blockage of BMP signaling [124]. 
These studies clearly demonstrate a critical role of ALK6-transduced BMP signaling in 
osteoblast differentiation and bone formation.  
As far as the type II receptor, BMPRII, it is necessary to phosphorylate the GS box in 
type I receptors. Without it coupling with a type I receptor, it was thought that no BMP 
signaling would be transduced. However, with lack of BMPRII, smooth muscle cells 
tranduce signals through another type II receptor, ActRIIa [125]. This suggests net gain of 
ligands to other BMP receptors in case of absent or non-functional BMPRII. 
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Chapter 2 
Specific aims 
 
Autologous bone grafting has been the gold standard in repair of bone defects but the 
complications with donor sites have led to the use of alternatives as synthetic materials, 
xenogenic or allogeneic bone despite their inconsistent performance. Addition of growth 
factors like bone morphogenetic proteins (BMPs) to bone graft substitutes to improve bone 
formation has been extensively studied. However, there are still several problems for the 
clinical use of BMPs including high cost and inconsistent results. Despite the extensive 
research particularly with BMP-2, little is known about the extracellular regulators that 
promote BMP functions. Very recently, our laboratory has reported that biglycan (BGN) 
positively affects BMP-2 signaling through its binding to BMP-2 and its type I receptor, 
ALK6, resulting in enhanced osteoblast differentiation in vitro. The studies in this 
dissertation aim to elucidate more on the mechanisms by which BGN promote BMP function 
by analyzing the role of BGN GAGs vs. its core and by determining which domain is most 
promising as a future clinically useful BMP agonist. The following specific aims were 
pursued: 
1. To determine the role of GAGs of BGN on BGN-assisted BMP-2 functions in vitro 
by utilizing a well recognized BMP-2 responsive cell system (i.e. C2C12 cells) and in 
vivo by utilizing a well established critical-sized rat mandible defect model. 
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2. To characterize the effect of BGN core protein on BMP-2 induced osteogenesis in 
vivo in a rat mandible model by μCT and histological analyses. 
3. To determine the effect of BGN core protein domains on BMP-2 function in vitro and 
in vivo. 
 
 
  
 
Chapter 3 
 
Study I 
 
Role of glycosaminoglycans of biglycan in bone morphogenetic protein-2 signaling 
by Miguez PA, Terajima M, Nagaoka H, Mochida Y, Yamauchi M. 
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Abstract 
Recently we have reported that biglycan (BGN) promotes osteoblast differentiation and that 
this function is due in part to its ability to positively modulate bone morphogenetic protein 
(BMP) functions. In this study we investigated the role of glycosaminoglycans (GAGs) of 
BGN in this function using in vitro and in vivo models. Methods: C2C12 myogenic cells 
were treated or untreated with BMP-2 alone or in combination with glycanated, partially 
glycanated or de-glycanated BGN, and the effects on BMP signaling and function were 
assessed by Smad1/5/8 phosphorylation and alkaline phosphatase (ALP) activity. 
Furthermore, the effect of de-glycanation of BGN on BMP-2 induced osteogenesis was 
investigated employing a rat mandible defect model. The defects were filled with collagen 
scaffolds loaded with glycanated, partially glycanated or de-glycanated BGN alone or in 
combination with a sub-optimal dose of BMP-2 (subBMP). Results: In in vitro experiments, 
BMP signaling and function were the greatest when BMP-2 was combined with de-
glycanated BGN among the groups tested. In the rat mandible experiments, µCT analyses 
revealed that the newly formed bone was significantly increased only when subBMP was 
combined with de-glycanated BGN. Conclusion: The data indicate that the GAG component 
of BGN functions as a suppressor for the BGN-assisted BMP function.  
Keywords: biglycan, BMP-2, C2C12 cells, Smad pathway, microcomputed tomography, 
osteogenesis 
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Introduction 
Small leucine rich proteoglycans (SLRPs) are a large family of extracellular matrix proteins 
composed of a core protein that includes 10-20 leucine-rich repeats (LRRs) and covalently 
bound glycosaminoglycan chains (GAGs) [1, 2]. The latter are highly negative-charged 
polymers of repeating disaccharides. One of the key functions of SLRPs in the extracellular 
matrix is the modulation of growth factor functions through its core protein or GAG 
component. [3, 4]. Biglycan (BGN) is a multifunctional Class I SLRP member playing roles 
in collagen assembly [5, 6], regulation of inflammation by interacting with TLR 2 and 4 
receptors [7, 8], binding and modulation of transforming growth factor (TGF)-β [3, 9] and 
bone morphogenetic protein (BMP)-2 and -4 functions [10, 11].   Previously, we have 
demonstrated that BGN promotes osteoblast differentiation, accelerates and increases matrix 
mineralization in vitro, and enhances the formation of a highly organized mineralized matrix 
in vivo [12]. These functions could be due to the capability of BGN to bind BMP-2/4 and 
their receptors [10, 11, 13]. However, the binding- and/or functional domains of BGN for its 
positive modulation of BMP functions are unknown. In this study, we investigated the role of 
GAGs of BGN in the BGN-assisted BMP-2 functions employing both in vitro and in vivo 
models.  
 
Experimental procedures 
Generation of partially glycanated, de-glycanated BGN and non-glycanated recombinant 
BGN 
GAG containing BGN (glycanated) purified from bovine articular cartilage was 
commercially obtained (Sigma-Aldrich, St. Louis, MO), suspended in distilled water 
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(2µg/µl) and an aliquot (4µl) was treated with chondroitinase-ABC (C-ABC) (Seikagaku, 
Tokyo, Japan) overnight at 37°C [14]. Two concentrations of C-ABC, i.e. 0.3U and 
0.1U/100µg of protein were used to generate de-glycanated or partially glycanated BGN. C-
ABC alone, C-ABC treated and non-treated BGNs were subjected to 4-12% SDS-PAGE and 
stained with Coomassie brilliant blue R-250 (CBB, Bio-rad, Hercules, CA) to confirm the 
extent of de-glycanation of BGN.  
Non-glycanated, glutathione S-transferase (GST)-fused BGN and GST-protein were 
generated in bacteria as previously described [11]. Briefly, the primer sequences of mouse 
Bgn cDNA corresponding to its mature core protein (amino acids 38-369; Asp38-Lys369) 
were designed as in Mochida et al., 2006 [11]. The PCR products amplified were then ligated 
into pGEX4T-1 vector (GE Healthcare, Waukesha, WI), sequenced, and the plasmid 
harboring the mature Bgn cDNA (pGEX4T-1-Bgn) was obtained. The pGEX4T-1-Bgn or 
pGEX4T-1 empty vector was transformed into BL21-CodonPlus bacterial strain (Stratagene, 
La Jolla, CA), and GST-BGN or GST protein was synthesized. Supernatants of the bacterial 
lysates were incubated with glutathione-sepharose beads (Amersham Biosciences, 
Piscataway, NJ) and the eluted proteins were dialyzed against distilled water and lyophilized. 
The identity and purity of the proteins generated were confirmed on SDS-PAGE and Western 
blot (WB) analyses with anti-BGN polyclonal antibody LF-159 (generous gift from Dr. Larry 
W. Fisher at NIDCR, Bethesda, MD) and anti-GST antibody (Sigma)[11]. 
 
Alkaline phosphatase activity 
The BMP function was assessed by the C2C12 cell assay system previously described [11, 
15, 16]. The mouse C2C12 myoblastic cells were obtained from American Type Culture 
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Collection (ATCC, CRL-1772). Cells were maintained in Dulbecco’s modified Eagle’s 
medium (DMEM, Invitrogen, Carlsbad, CA) as described [11, 16]. C2C12 cells were 
untreated or treated with glycanated BGN (4µg), C-ABC alone, BMP-2 (R&D Systems, 
Minneapolis, MN) (150ng), BMP-2 + glycanated BGN or BMP-2 + C-ABC treated BGN 
(0.3U/100µg of protein) (de-glycanated). After 3 days of culture, the cell lysates were 
collected and subjected to Alkaline phosphatase (ALP) activity in the same manner as 
described [11, 16]. ALP assay was performed in triplicate and the values obtained were 
subjected to factorial analyses One-Way ANOVA and Tukey at 95% confidence interval 
using JMP 8.0 software (SAS, Charlotte, NC). 
 
Smad phosphorylation assay 
The effect of GAGs of BGN on BMP signaling was assessed by the extent of the Smad1/5/8 
phosphorylation in C2C12 cells. BGN glycanated, partially glycanated and de-glycanated 
with BMP-2 (see above) were added to cell culture medium. Cell extracts were then applied 
to 4-12% SDS-PAGE followed by WB analyses with anti-phospho-Smad1/5/8 antibody (Cell 
Signaling, Danvers, MA) or anti-β actin antibody (Cell Signaling) for normalization. 
To assess a possible effect of C-ABC on BMP signaling, two control groups were 
investigated for Smad phosphorylation: C-ABC + BMP-2 (150ng), and C-ABC + GST-BGN 
(non-glycanated) + BMP-2. 
 
Effect of removal of GAGs of BGN in in vivo bone formation 
The protocol of animal experiments was approved by the Institutional Animal Care and Use 
Committee (IACUC) at the University of North Carolina at Chapel Hill (IACUC ID: 09-
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237.0). To investigate craniofacial bone regeneration using BGN and BMP, 5mm-critical-
sized defects were generated in mandibles of sixteen Sprague-Dawley male breeder rats 
weighing ~525g [17-20]. According to Arosarena et al., 100ng of BMP-2 is considered as 
“sub-optimal” dose of BMP as defects exhibit minimal osteogenesis even after 8 weeks of 
healing [20]. Thus, this “sub-optimal” dose of BMP (subBMP) was used to evaluate the 
effect of BGN on BMP-induced bone formation. Briefly, all animals were given a pre-
operative dose of antibiotic Cefazolin (10mg/kg). Anesthesia was achieved by Ketamine (80 
mg/kg)/Xylazine (10 mg/kg). Two cm incisions were made along the inferior border of the 
hemi-mandibles and the masseter muscle and periosteum detached to expose the ramus. 
Using a 5mm-diameter trephine (Salvin Dental, Charlotte, NC), a critical-sized defect was 
placed at the ramus ~3mm above the lower border of the mandible and 2mm distal to the 
incisor root (Fig 3.3). The defects were unfilled or filled with a UV-cross-linked collagen 
sponge (Nitta Gelatin, Japan) as a scaffold. Each scaffold precut with a 5mm-diameter tissue 
punch (Miltex Incorporated, York, PA) was soaked uniformly in 10µl total solution of 
phosphate buffer saline containing the experimental protein groups. Control groups included: 
1. unfilled, 2. collagen scaffold-filled with glycanated BGN, 3. collagen scaffold-filled with 
de-glycanated BGN [0.3U/100µg protein], and 4. C-ABC alone (a total of 4 control groups 
without any addition of subBMP). Treatment groups received the scaffold loaded with: 5. 
subBMP alone or combined with 6. glycanated BGN, 7. de-glycanated BGN, or 8. C-ABC (a 
total of 4 treatment groups). For each group, 2 rats were used. The muscle layer was tightly 
sutured with 5-0 chromic gut (Ethicon, Somerville, NJ) and the skin with 4-0 polypropylene 
suture (Ethicon) and the rats were maintained on a diet of soft rat chow (Harlan Taklad, 
Indianapolis, IN) and water for 4 days.  
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Microcomputed tomography 
At 2 weeks post-surgery, all animals were euthanized, the mandibles were removed, fixed 
with 10% formalin for 3 days, and µCT scanning (Scanco Medical µCT 40, Bruttisellen, 
Switzerland) was  performed. The X-ray parameters were 70kVp at 114uA with a 200ms 
integration time. 
Image matrix size was 2048 x 2048 with acquired 2000 projections over a  
360 degree rotation.  A tube of 20.5mm diameter which allows a pixel size  
of 10µm was used. Acquisitions were made using a conebeam geometry and a Feldkamp 
filtered backprojection reconstruction algorithm used to create the  
reconstructions. All samples were positioned and scanned in a standard manner using an 
airtight cylindrical sample holder filled with PBS. For the analyses of the acquired images, 
the CTAn analyser software 1.9.1. (Skyscan, Kontich, Belgium) was used. The region of 
interest was selected in all images through a standardized drawing of the area within the 
defect borders. The region was first positioned in the middle of the surgical defect and it was 
then extended to all slices of the data set. A new drawing was done every 20 images. 
Quantitative morphometric analysis of the mineralized tissue inside the defects was carried 
out on voxels that corresponded to bone. After tomographic acquisitions, 3D images were 
reconstructed through direct volume rendering from the series of 2D projections.  
 
Results 
GAG removal enhances BGN-assisted BMP-2 function 
For the removal of GAGs, glycanated BGN was treated with several concentrations of C-
ABC and the release of the core protein was examined by SDS-PAGE. At the concentration 
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Figure 3.1. Generation of de-glycanated BGN and its effect on BMP-2 function. (A) SDS-PAGE of BGN without (lane 1) 
and with (lane 2) chondroitinase ABC (C-ABC) treatment. A bracket indicates C-ABC. An arrow head indicates the core 
protein of BGN. (B) ALP activity in C2C12 cells. Note that BMP-2 induced ALP activity is significantly increased by the 
addition of glycanated BGN (lane 5) but the effect is further enhanced by de-glycanation of BGN by C-ABC treatment (lane 
6) (p<0.05). ++ of C-ABC: 0.3U/100μg, + for BGN and BMP-2 are 4µg and 150ng, respectively. © Printed with permission 
from Elsevier. Miguez et al., Role of glycosaminoglycans of BGN in BMP-2 signaling. BBRC 2011; 405(2): 262-6. 
 
of 0.3U/100µg of protein (denoted as ++), the core protein (~45 kDa) was efficiently released 
(Fig 3.1A, lane 2) (also see below), which is consistent with the report by Matsuno et al., 
2007[14]. The effects of glycanated and de-glycanated BGN on BMP-2 function were 
evaluated by ALP activity (Fig 3.1B). No treatment (lane 1) or treatment with BGN (lane 2) 
or C-ABC alone (lane 3) did not exert significant ALP activity. The BMP-2 induced ALP 
activity (lane 4) was significantly increased with the addition of glycanated BGN (lane 5), 
but the increase was further enhanced with de-glycanated BGN (lane 6) (p<0.05).  
The levels of GAGs of BGN affect the enhancement of BGN-assisted BMP-2 signaling 
Figure 3.2A shows BGN core protein band when it was untreated (lane 1) or treated with 
0.3U/100 μg (++) (lane 2) or 0.1U/100 μg of C-ABC (+) (lane 3). As demonstrated, C-ABC 
treatment at a concentration of 0.3U/100 µg (++) was sufficient to generate a distinct BGN 
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Figure 3.2. Effects of partially- and fully de-glycanated BGN on BMP-2 signaling. + of C-ABC: 0.1U/100µg of 
protein and ++: 0.3U/100µg of protein. + for BGN and BMP-2 are 4µg and 150ng, respectively. (A) BGN 
(glycanated) (lane 1), BGN treated with chondroitinase-ABC (C-ABC) at a concentration of ++ (lane 2) or + (lane 3).  
Note that only partial de-glycanation was achieved with the latter treatment. (B) Effects of glycanated, partially- (C-
ABC +) and fully (++) de-glycanated BGN on BMP-2 signaling measured by Smad1/5/8 phosphorylation. BMP-2 
induced signaling (lane 4) was increased by glycanated BGN (lane 2), and it was further enhanced by de-glycanation 
of BGN with C-ABC (lanes 5-6). Note that the fully de-glycanated BGN (lane 5) shows higher signaling compared to 
that of partially glycanated (lane 6). C-ABC alone with BMP (no BGN) did not enhance BMP signaling (lane 7). (C) 
Effect of C-ABC treatment on GST-BGN-enhanced BMP-2 signaling. C-ABC did not increase the effect of GST-
BGN (lane 5). GST-BGN: glutathione S-transferase fused BGN. © Printed with permission from Elsevier. Miguez et 
al. Role of glycosaminoglycans of biglycan in BMP-2 signaling. BBRC 2011 405(2): 262-6. 
 
core band at ~45kDa (lane 2) (de-glycanated). Use of higher concentrations of C-ABC did 
not change the level of core protein indicating that the BGN is likely fully de-glycanated with 
this concentration of C-ABC (data not shown). With a concentration of 0.1U/100 μg (+) the 
BGN core appeared as a smear band with a slightly higher molecular weight indicating that 
the GAGs were not fully removed (i.e. partially glycanated). 
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Fig 3.2B shows the effects of de-glycanation of BGN on BMP-2 signaling assessed 
by Smad1/5/8 phosphorylation. Without treatment (lane 1) or treated with BGN alone (lane 
3) C2C12 cells did not induce Smad phosphorylation. When glycanated BGN was added to 
BMP-2 (lane 2), the signaling level was increased when compared to that of BMP-2 alone 
(lane 4). This positive effect was further enhanced with de-glycanated BGN (lane 5), but the 
enhancement was decreased with partially glycanated BGN (lane 6). C-ABC alone did not 
affect the BMP-2 signaling (lane 7).  The results indicate that though all BGN species exerted 
positive effects on BMP-2 signaling, the enhancement levels were inversely correlated with 
the level of GAGs. The positive effect of non-glycanated BGN was further confirmed by the 
use of recombinant GST-BGN (Fig 3.2C). The GST-BGN alone did not induce the BMP-2 
signaling (lanes 1 and 3). The BMP-2 induced signaling (lane 2) was enhanced with the 
addition of GST-BGN (lane 4). Addition of C-ABC to (GST-BGN + BMP-2) did not 
increase the (GST-BGN + BMP-2) induced signaling (lane 5) confirming the lack of C-ABC 
effect on BMP-2 signaling (also see Fig 3.2B, lane 7). GST protein alone showed no effect as 
we previously reported [11]. 
 
De-glycanated BGN enhances BMP-2 induced osteogenesis 
Figure 3.3 shows the representative 3D and 2D µCT images obtained from similar 
anatomical areas including the defects (indicated by dotted line) at the 2 week post-surgery. 
The graph at the bottom shows the bone volume (BV) of newly formed bone (NFB) in the 
defects. The NFB in the subBMP group (lane 1) was similar to those of control groups (i.e. 
empty, collagen scaffold alone or filled with glycanated or de-glycanated BGN, or C-ABC 
alone) (data not shown). When subBMP was combined with glycanated BGN (lane 2) or C-
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Figure 3.3. µCT images corresponding to the rat mandible 5mm-surgical defects at 2 weeks post-surgery. subBMP: sub-
optimal BMP-2 (100ng), BGN:4μg. (A) Schematic representation of rat mandible and defect location on the left. On the 
right, top panel shows 3D µCT and lower panel 2D µCT views of the defects treated with subBMP dose without (lane 1) 
or in combination with BGN (glycanated) (lane 2), C-ABC (lane 3) or BGN/C-ABC (de-glycanated)(lane 4). Below, the 
median (represented by columns) and range (error bars) of bone volume (BV) of the newly formed bone (NFB) of 2 
defects per group of treatment 2 weeks post-surgery. © Printed with permission from Elsevier. Miguez et al., Role of 
glycosaminoglycans of BGN in BMP-2 signaling. BBRC 2011  405(2): 262-6. 
 
ABC (lane 3), the newly formed bone was unchanged or slightly lower when compared to the 
group of subBMP alone. However, when de-glycanated BGN was combined with subBMP, 
the NFB volume was markedly increased (lane 4).  
 
Discussion 
BGN was originally found in the mineral-associated compartment of bone suggestive of its 
role in mineralization [21]. In addition, it has been reported that BGN is highly present in the 
areas of growth of skeletal tissues and the cell surface of both chondroblasts and osteoblasts, 
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suggesting its role in modulating the cellular activity [22]. The study reported by Chen et al., 
2004 [10] was the first to propose a mechanism by which BGN could facilitate osteoblast 
functions. Independent of these studies, we have reported that BGN levels were “positively” 
correlated with the timing, extent and quality of matrix mineralization [12]. Also, Chen et al. 
and we further reported that BGN suppression resulted in poor response of osteoblastic cells 
to BMP [10, 12].  Furthermore, we demonstrated that BMP-induced ALP activity in C2C12 
cells was synergistically increased with the exogenous addition of GST-BGN and that BGN 
bound to BMP-2 and its type I receptor, ALK6, and possibly other receptors [11]. 
In the present study, we explored the potential role of GAG component of BGN on 
the BGN-assisted BMP function. Our study demonstrated that de-glycanation of BGN with 
C-ABC treatment significantly enhances the BGN-assisted BMP-2 signaling and function. 
The partial removal of GAGs obtained with a low concentration of C-ABC (0.1U/100µg) 
showed that the enhancement was indeed less potent compared to that of fully de-glycanated 
BGN.  
C-ABC alone did not potentiate BMP-2 signaling. In fact, an addition of C-ABC to 
GST-BGN rather tended to decrease the BMP-2 signaling (Fig 3.2C). C-ABC could cleave 
the GAGs of other proteoglycans present at the myoblastic cell surface and/or in the 
extracellular matrix in the cultures, which may affect BMP-2 signaling. Indeed, myoblasts 
are known to synthesize chondroitin sulfate (CS)/dermatan sulfate (DS) proteoglycans such 
as decorin and versican [23, 24]. Thus, higher doses of C-ABC (up to 4.0U/100µg) were also 
tested in combination with BMP-2, however, this caused even a further decrease in BMP-2 
signaling (data not shown). This suggests that the positive effect of de-glycanation on BMP 
function is specific to BGN.  
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The mechanism by which the GAG component suppresses the BGN assisted BMP-2 
function is not clear at this point. However, it is conceivable that the highly negative charged 
GAGs can sequester the basic protein, BMP-2, leading to reduced interaction between BGN 
core protein and BMP-2. During the preparation of this manuscript, a study was published on 
the effect of BGN on BMP-2 canonical and non-canonical pathways in MC3T3-E1 cells [25]. 
The authors found that glycanated BGN is able to increase the phosphorylation of ERK in 
addition to Smad 1/5/8. We have also investigated the effect of glycanated and de-glycanated 
BGN on ERK phosphorylation and found no effect in C2C12 cells (data not shown).  
The in vitro ALP and Smad phosphorylation data (Fig 3.1B and 3.2B, respectively) 
unequivocally demonstrated that de-glycanation of BGN greatly increases the BGN-assisted 
BMP-2 function and signaling.  A positive effect of de-glycanation of BGN on BMP-induced 
osteogenesis was also observed in the in vivo study, while glycanated BGN had no effect. For 
the results from in vivo study, a few possibilities should be considered. First, the glycanated 
BGN used in this study was purified from articular cartilage resulting as a protein with a 
mixture of CS and DS-GAGs (Sigma). The presence of those GAGs and the ratio of CS to 
DS in this sample could influence significantly BGN function as these disaccharides possess 
different affinity to calcium and hydroxyapatite (HAP)[26, 27]. Also, due to the increased 
structural flexibility, DS could function as an inhibitor of mineralization [28]. Second, is that 
BGN with GAGs may favor alternative interactions rather than with BMPs and/or its 
receptors. It has been reported that BGN highly interacts with macrophages stimulating 
secretion of pro-inflammatory molecules [7, 8], which could impair proper osteogenesis. 
Third, the release kinetics of glycanated vs. de-glycanated BGN from the collagen scaffold 
could be different. BGN has been found to weakly interact with collagen type I via both core 
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and GAGs [29]. However, if GAGs are present, the interaction is mainly through the 
disaccharides with a lower dissociation constant (Kd), i.e., stronger binding, than through 
core [30-32]. Thus, longer retention of glycanated BGN in the scaffold could have negatively 
affected the release of BGN to assist on BMP function. Further studies investigating the 
kinetics of (glycanated, de-glycanated) BGN release are warranted. However, it is clear that 
the removal of GAGs from BGN facilitates the BMP-2 induced osteogenesis in vivo, which 
is consistent with the in vitro data.   
In conclusion, these in vitro and in vivo results strongly indicate that the BGN core 
protein is responsible for its function in promoting the BMP-2 functions and that the GAG 
component could function as a suppressor in this process. BGN core protein could be used in 
clinical settings to enhance BMP-2 induced bone formation after the optimal conditions in 
vivo are established. The rat mandible defect model described is feasible and appears to be 
appropriate for these future studies. 
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Characterization of biglycan-assisted bone morphogenetic protein-2 induced 
osteogenesis in vivo 
by Miguez PA, Terajima M, Nagaoka H, Ferreira J, Ko CC, Yamauchi M. 
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Abstract 
In the previous study, we established that the positive effect of biglycan (BGN) on bone 
morphogenetic protein-2 (BMP-2) function was due to the core protein and that the 
glycosaminoglycan (GAG) component functions as a negative regulator (Study I). Thus, in 
this study, we generated glutathione-S-transferase (GST)-fused recombinant BGN (GST-
BGN) that lacks GAGs and tested its effect on BMP-2 function in vitro and in vivo. Methods: 
The effects of GST-BGN on BMP-2 function in vitro were evaluated using the myogenic 
C2C12 cells. After incubation with BMP-2 with and without GST-BGN, the cell lysates were 
analyzed for Smad1/5/8, β-catenin and ERK 1/2 phosphorylation and alkaline phosphatase 
(ALP) activity. In vivo, five-mm critical-size defects were generated in the hemimandibles of 
mature Sprague-Dawley rats. Control groups were unfilled or filled with a cross-linked 
collagen sponge alone or with GST or GST-BGN alone. Treatment groups received the 
collagen sponge with: suboptimal (subBMP/0.1µg) and optimal (optBMP/1µg) 
concentrations of BMP-2; and various doses of GST-BGN with subBMP.  At 2 weeks post-
surgery, the newly formed bone (NFB) in the defects was evaluated by µCT and histological 
analyses. Results: By C2C12 cell system assay, BMP-2 induced p-Smad 1/5/8 and ALP 
activity were enhanced by GST-BGN. In vivo, µCT and histological analyses showed little 
NFB in the controls, subBMP and (subBMP + 2µg of GST-BGN) groups. The optBMP 
group showed significant amounts of NFB that was ectopically formed. The greatest amounts 
of NFB that was associated with the collagen sponge were seen with subBMP + 4 and 8 µg 
of GST-BGN.  The analyses employing µCT, Masson’s trichrome and picrosirius red (PSR) 
staining suggested that the (subBMP + GST-BGN) groups may exhibit less porous, more 
compact and organized bone matrix when compared to optBMP. Wnt signaling was 
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significantly upregulated in BGN-treated rats at 2 weeks. OptBMP NFB seemed to have the 
highest turnover as per presence of TRAP positive cells and green/orange PSR pattern. 
Conclusion: These data indicate that GST-BGN predictably promotes the BMP osteogenic 
function in vitro and in vivo without compromising the matrix quality.  
Keywords: biglycan, BMP-2, Smad 1/5/8, osteogenesis, β-catenin, Wnt 
59 
 
Introduction 
Craniofacial bone defects of congenital and/or acquired origin, e.g. age-associated bone loss, 
cleft palate and lip, periodontal disease, odontogenic tumors, etc, are a major health threat to 
our society directly affecting the quality and length of life. Today, more than 500,000 bone 
grafting operations are performed annually in the US in an attempt to regenerate bone in the 
orofacial area alone [1]. Autograft has been the gold standard, but the morbidity and the 
requirements of a large quantity of bone and the second surgical sites are of significant 
problems. Allografts may provoke immune rejection and alloplastic bone substitutes 
generally exhibit poor (or no) bone integration and bone induction [2, 3]. To resolve these 
problems, an approach of “tissue engineering” consisting of a biocompatible scaffold, 
osteogenic growth factors such as bone morphogenetic proteins (BMPs) and stem cells, has 
been developed [4-6]. The clinical use of BMPs combined with various scaffolds is 
promising but still faces serious limitations, e.g. high cost, requirement of high quantities of 
BMP, difficulties to retain BMP in situ, etc.  
Recently, we have shown that BGN is a potent positive modulator of BMP function 
and increases osteoblast differentiation and mineralization [7]. Most recently, we also have 
established that this function is exerted primarily through BGN core protein and that the 
glycosaminoglycan (GAG) component of BGN functions as a suppressor (see Chapter 3, 
study I and Miguez et al., 2011[8]). In this study we further investigated the effect of 
recombinant BGN (devoid of GAGs), i.e.  glutathione-S-transferase (GST)-fused BGN 
(GST-BGN), on BMP signaling and functions by C2C12 cell assay system.  In addition, we 
investigated the efficacy of several doses of GST-BGN on BMP-2 function in vitro and in 
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vivo by using several doses of BGN. For in vivo, we tomographically and histologically 
characterized the newly formed bone (NFB) in a rat mandible model by means of bone 
volume, collagen organization, osteoclastic activity and BMP signaling.  
 
Experimental Procedures 
Cell line and culture conditions 
C2C12 cells were cultured as previously described by Mochida et al., 2006 [9]. Briefly, cells 
were purchased from American Type Culture Collection (ATCC, cat# CRL1772). Cells were 
grown in DMEM (Invitrogen, Carlsbad, CA) with high glucose (4.5g/l) containing 15% FBS 
(Invitrogen) and supplemented with 100 U/ml of penicillin G sodium and 100 µg/ml 
streptomycin sulfate. Cells were cultured at 5% CO2 atmosphere at 37˚C and the medium 
was changed twice a week. 
Generation of recombinant BGN and verification of effect on BMP-2 function 
The generation and purification of recombinant BGN in E. coli system fused with 
glutathione-S-transferase tag (GST-BGN) has been previously published by Mochida et al., 
2006 [9] and briefly described in Chapter 3, Study I [8] . After purification, the purity of 
GST-BGN was assessed by SDS-PAGE stained with Coomassie Brilliant Blue (CBB, Bio-
rad, Hercules, CA) and Western blot (WB) with anti-GST (Sigma) antibody. The effect of 
GST-BGN on BMP-2 function was confirmed by ALP activity as described [9]. The dose-
effect of GST-BGN on BMP-2 signaling was evaluated by adding 2, 4 or 8 µg of GST-BGN 
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combined with BMP-2 to C2C12 cells followed by the measurement of phosphorylation of 
Smad 1/5/8. 
Smad 1/5/8, β-catenin and ERK 1/2 phosphorylation  
The effect of GST-BGN on canonical (Smad) and non-Smad BMP-2 signaling pathways was 
assessed by the phosphorylation of Smad1/5/8, β-catenin and ERK 1/2  in C2C12 cells. 
Briefly, 4 µg of GST-BGN and 150 ng of BMP-2 (R&D, Minneapolis, MN) were added to 
the cell culture medium. Cell extracts were then applied to 4-12% SDS-PAGE followed by 
WB analyses with anti-phospho (p)-Smad1/5/8 (Cell Signaling, Danvers, MA), anti-p-β-
catenin antibody (Cell Signaling) or anti-p-ERK 1/2 (Cell Signaling). The levels of 
pSmad1/5/8 and pErk1/2 were normalized to β actin (Cell Signaling), and p-β-catenin to total 
β-catenin (Cell Signaling).  These experiments were performed in duplicate. 
Surgical procedure and euthanasia  
The surgical procedures were carried out in the same manner as described in Chapter 3, 
Study I [8].  For this study, 18 rats were used (2/group). As stated above, according to 
Arosarena et al. [10], 100ng of BMP-2 is considered a “sub-optimal” dose of BMP as defects 
exhibit minimal osteogenesis even after 8 weeks of healing. In this same study, the authors 
concluded that 1 µg was an “optimal” dose to promote accelerated and increased bone 
regeneration of the mandible, completely closing the defect in as early as 2 weeks. Thus, this 
“sub-optimal” dose of BMP (subBMP) was used to evaluate the effect of GST-BGN doses on 
BMP-induced bone formation. The “optimal” dose of BMP (optBMP) was used as a means 
of comparison of the amount and quality of bone formed with and without BGN assistance.  
Control groups included: 1. unfilled defect, 2. collagen scaffold alone, 3. collagen scaffold-
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filled with GST-BGN or GST-protein alone (a total of 4 control groups without any addition 
of subBMP). Treatment groups received the scaffold loaded with: 4. subBMP alone or 
combined with 5. 2 µg of GST-BGN, 6. 4µg of GST-BGN, or 7. 8 µg of  GST-BGN  and 9. 
optBMP (a total of 5 treatment groups).  For each group, 2 rats were used. Rats were 
euthanized after 2 weeks of surgery. 
Microcomputed tomography 
The handling of the mandibles after euthanasia and µCT specifications and procedures were 
described in Chapter 3, Study I [8]. 
Measurement of bone volume and porosity 
Bone volume (BV) and porosity were measured by selecting the region of interest in 
all images through a standardized drawing of the area within the defect borders as described 
above. The region was first positioned in the middle of the surgical defect and it was then 
extended to all slices of the data set. A new drawing was done every 20 images. The scans 
were converted into a binary image and bone volume was determined by dividing BV/ total 
area (TA). Results are reported as the median (columns) and the range (error bars) of the 
NFB in two defects per group. For the calculation of bone volume and porosity, a threshold 
of 850mg/cm3 was considered optimal for the distinction of the NFB. The percentage of 
porosity was computed by dividing the bone area (recognized by the computer/software 
based on the threshold established) by section area x 100 [11]. 
Histological preparations and analyses 
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The rats mandibles were harvested 2 weeks after the surgery, and after µCT measurements 
they were fixed in 10% buffered formalin (Sigma-Aldrich, St. Louis, MO), part of the soft 
tissues were removed and they were demineralized in 0.5 M EDTA (Fisher Scientific, 
Waltham, MA), pH 7.4 for 8 weeks. The samples were dehydrated in several ascending 
gradations of ethanol (50-100%), soaked in xylene and embedded in paraffin. Several 
sections from each mandible paraffin block were cut by using a microtome Leica Jung 
RM2045. Several sections were cut from each mandible within the middle of the 5mm defect 
and three sections were chosen for staining by each of several histological protocols. Sections 
were stained by Masson’s trichrome [12] for histomorphometry, by Picrosirius red staining 
(PSR) [13, 14] for collagen organization, by immunohistochemistry (IHC) for bone 
sialoprotein (BSP) (Cell Signaling), p-Smad 1/5/8 (Cell Signaling), p-β-catenin (Cell 
Signaling), and p-ERK 1/2 (Cell Signaling) and by TRAP [15]. Sections were observed with 
a light microscope Olympus BX40 (with polarized light for PSR) at 4x to 40x  magnification. 
High magnification images were taken from NFB immediately adjacent to the native bone 
for PSR and Smad, representative areas for TRAP and adjacent to the NFB and middle of the 
defect for BSP and β-Catenin. For histomorphometric analyses, the total area (TA) of the 
defect was outlined in two representative mid sections of Masson’s trichrome staining from 
each rat within each group of treatment (n=4). The areas of interest (NFB) within the defects 
(TA) were outlined by using Image J software drawing tools. The histological bone area 
(BA) of NFB was calculated as NFB/TA. Image J is an image measurement software freely 
available from NIH.  
 
Results 
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Fig 4.1. A. Purity of GST-BGN and GST-protein by SDS-PAGE and WB (anti-GST). B. GST-BGN shows about 
70kDA and GST about 25kDA. B. ALP activity demonstrating that BMP-2 (lane 4) has increased ALP compared to 
controls (no treatment (Tx) (lane1), GST (lane 2) and GST-BGN (lane 3). BMP2 + GST (lane 5) has similar ALP to 
BMP-2 alone. GST-BGN significantly increased BMP-2 induced ALP activity in C2C12 cells (lane 6). C. Dose 
dependent effect of GST-BGN on BMP-2 signaling. 2µg of GST-BGN significantly increased phosphorylation of Smad 
1/5/8 (lane 3). 4µg of GST-BGN further increased signaling (lane 4) but 8µg did not further enhanced the effect. D. 
Signaling pathways upon BMP-2 and BMP-2 + 4 μg GST-BGN. Upper panel shows GST-BGN significantly enhanced 
BMP-2 induced Smad phosphorylation (lane 3). Middle panel shows no significant increase in phosphorylated β-
catenin with any of the treatments. Lower panel shows that BMP-2 reduced p-Erk 1/2 (lane 2) and addition of GST-
BGN did not alter that signaling pattern (lane 3). 
 
 
Effect of GST-BGN on BMP signaling and function in vitro  
As shown in Fig 4.1A, both SDS-PAGE and WB analyses for the newly generated GST-
BGN and GST showed the single bands at the expected migration positions at ~70 (45 kDa 
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BGN core + 25 kDa GST) (lanes 1, 3) and 25 kDa (lanes 2 and 4), respectively, thus, 
confirming the purity.  The positive effect of GST-BGN addition on BMP-2 induced ALP 
activity was also confirmed (Fig 4.1B). The effect on BMP-2 signaling was analyzed by 
Smad 1/5/8 phosphorylation and shown in Fig 4.1C. The phosphorylation was induced with 
BMP-2 (lane 1, 2) and it was enhanced with the addition of 2 μg of GST-BGN (lane 3). The 
signaling was further intensified with 4 μg of GST-BGN (lane 4) and stayed that level with 8 
μg (lane 5).  
Figure 4.1D shows the comparison of Smad and non-Smad signaling in C2C12 cells 
induced by BMP-2 with and without 4 μg of GST-BGN. Smad 1/5/8 phosphorylation was 
enhanced by GST-BGN in BMP-2 treated C2C12 cells (upper panel). However, β-catenin 
phosphorylation did not significantly change with BMP-2 with or without GST-BGN (middle 
panel, lane 2). Erk 1/2 phosphorylation was clearly reduced with BMP-2 (lane 2) and the 
addition of GST-BGN (lane 3) had no significant effect.  
 
Tomographic bone volume (BV) and porosity of the newly formed bone (NFB) in the rat 
mandibles treated with BMP-2 or BMP-2 combined with GST-BGN 
Figure 4.2 shows the representative 3D (upper panel) and 2D (middle panel) µCT images 
obtained at 2 weeks post-surgery. Lower panel shows quantification of bone volume (BV). 
The BV values of control groups, i.e. unfilled, scaffold alone, scaffold + GST, scaffold + 
GST-BGN (not shown) were all slightly lower than that of subBMP (lane 1). Compared to 
these groups, the levels of NFB were significantly higher in the optBMP (lane 2). However, 
the bone formed by optBMP appeared to be mainly ectopic in nature, not filling the defect 
area and quantification of BV showed that NFB occupied less than 80% of the defect area. 
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Fig 4.2. μCT analyses of the rat mandibles showing 3D (upper panel) and 2D (middle panel) views of the mandibles. 
Lower panel shows the bone volume (BV) quantitated by CT. Note that optBMP (lane 2) shows tendency of greater BV, 
however, it is of ectopic nature.  SubBMP + GST-BGN show defects filled with newly formed bone (NFB) within the 
boundaries of the defect (lane 4 and 5). 
 
Incorporation of 2µg of GST-BGN into the scaffold in combination with subBMP-2 (lane 3) 
did not significantly enhance bone formation compared to subBMP-2 alone. When subBMP 
was combined with 4 and 8µg of GST-BGN, a significant increase in bone formation was 
achieved (lane 4 and 5, respectively). 
Porosity calculated by the µCT software CTan Analyzer (Skyscan, Kontich, Belgium) 
within the NFB in the defect boundaries showed that subBMP and optBMP groups had 30% 
and 53% porosity, respectively. The subBMP + GST-BGN groups showed similar porosity 
for all three groups averaging 25% [11]. 
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Fig 4.3. Masson’s trichrome staining and histological calculation of  bone area (BA). A. scaffold alone. Arrow: newly 
formed bone (NFB) due to periosteum release, B. subBMP, C. optBMP. D. subBMP + 2µg GST-BGN, E. subBMP + 
4µg of GST-BGN, F. subBMP + 8µg of GST-BGN. Yellow solid line around native bone. Yellow dotted line around 
NFB. Lower graph shows quantification of BA (NFB/TA) by Image J within the defect area of 2 rats per group. Bars 
are medians and error bars are variations. subBMP: suboptimal dose of BMP-2/100 ng, optBMP: optimal dose: BMP-
2/ 1μg. 
 
Histological evaluation 
Masson’s trichrome staining 
Trichrome staining shows in blue color the collagen rich tissues either represented by native 
or newly formed bone or by fibrous tissue present between the defect borders. Fibrotic tissue 
shows loose fibers lightly stained in blue with no recognizable bony architecture (i.e. 
lamellar or trabecular structure). Muscle is stained in red. In figure 4.3, for easy of 
identification the edge of NFB is delineated by dotted yellow line and the native bone by 
solid line. The presence of NFB as a result of periosteum release around native bone was 
evident in all samples as shown by an arrow in the scaffold alone group (Fig 4.3A). The other 
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control groups showed minimal bone formed at the edge of the defect (not shown). SubBMP 
group showed a small and compact NFB (Fig 4.3B). OptBMP group showed a much greater 
amount of NFB compared to subBMP (Fig 4.3C). However, in both rats of this group, the 
pattern of osteogenesis was ectopic with bone formed outside of the defect area, i.e. (within 
muscle). Fig 4.3D, E and F show the images obtained from the subBMP groups combined 
with 2, 4 and 8 μg of GST-BGN, respectively.  While NFB did not change with the addition 
of 2μg of GST-BGN (Fig 4.3D), it was significantly increased with 4μg of GST-BGN (Fig 
4.3E) and further enhanced with 8 μg of GST-BGN (Fig 4.3F). These changes were 
confirmed by histomorphometric analyses (lower panel of Fig 4.3). No cartilage-like tissues 
(based on morphology) were found in any of the samples. 
BSP 
Among the non-collagenous proteins investigated as markers of osteoblast differentiation 
some are also involved in calcification of bones (i.e. osteonectin, osteopontin, BSP and 
osteocalcin). BSP has been mostly attributed to deposit of calcium and regulation of HAP 
crystal growth just before mineralization (see review [16]. BSP is involved in upregulation of 
Cbfa1 and ALP activity in osteoblasts in vitro as well as in critical-sized defects in calvaria, 
thus, its presence may indicate continuous stimulation of osteoblast differentiation  in in vivo 
models [17-19]. Immunohistochemical staining for BSP showed no significant 
immunostaining within the defect area in the control groups (data not shown). The subBMP 
group had some immunoreactivity around the NFB bone (dotted line) but mostly 
undetectable in the middle of the defect (between continuous lines) (Fig 4 A, B). The 
optBMP groups showed significant immunoreactivity around the NFB (dotted lines, Fig 
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Figure 4.4. Bone sialoprotein (BSP) in the rat mandibles. A. subBMP group showing minor amounts of BSP adjacent to 
newly formed bone (NFB) (dotted line). B. No significant reactivity in the middle of the defect (main stream of the defect 
is delineated with solid line). C. optBMP group with BSP present within and adjacent to NFB. D. Significant 
immunoreactivity for BSP present within non mineralized areas. E. subBMP + 2 μg of GST-BGN group with BSP 
adjacent to NFB (dotted line). F. Immunoreactivity also present in the middle of the defect. G. subBMP + 4μg GST-BGN 
group with stronger BSP expression compared to subBMP alone (A), adjacent to NFB. H. Immunoreactivity strongly 
present in the middle of the defect. I. subBMP + 8μg group with BSP found adjacent to NFB (dotted line). J. BSP is found 
highly present in the middle of the defect. Scale bar is 200μm on B.  
 
4.4C) as well as in the mid-area where mineralization was still not evident (Fig 4.4D). The (2 
µg of recombinant BGN + subBMP) group showed more immunoreactivity compared to 
subBMP alone (Fig 4.4E, F). With increasing doses of GST-BGN, the immunoreactivity for 
BSP was proportionally stronger (Fig 4.4G, H, I, J). The highest dose of BGN with subBMP 
showed intense, patch-like staining for BSP in the non-mineralized areas (Fig 4.4I, J) 
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Fig 4.5. Picrosirius red (PSR) staining of rat mandibles. SubBMP group appears with red collagen fibers. B. High 
magnification of boxed area. C. optBMP group appears with green/yellow to orange collagen fibers. D. High 
magnification of boxed area. E. subBMP + 8μg GST-BGN group showing yellow to red collagen fibers in the NFB 
area. F. High magnification of the boxed area. Scale bar on A is 500μm and on B is 200μm. 
 
possibly indicative of concentrated deposition of BSP which could indicate faster 
mineralization compared to other groups. This was present for both sections in both rats for 
this group.  
Picrosirius red (PSR) staining  
The organization and maturation of fibrillar collagen matrices in the controls and treatment 
groups were assessed by PSR staining and shown in Fig 4.5. The collagen matrix in the 
defects in controls, thus non-mineralized, were thin and not visible under polarized light 
(data not shown). As shown in Figure 4.5A and B, the collagen matrix of the NFB in the 
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Fig 4.6. TRAP staining for osteoclastic activity in the rat mandibles. Trap positive sections were found for both rats treated 
with optBMP dose (A,B). Arrows indicate positive cells. Negative TRAP activity in subBMP + 4μg (C) and 8μg (D) GST-
BGN treated groups. Scale bar on A is 200μm.  
 
subBMP group was organized, mature and thick, as indicated by the intense red staining of 
the collagen fibers. On the other hand, the NFB of optBMP group showed faint orange to red 
color with patches of green color indicating that the collagen matrix is less mature and less 
organized (4.5C, D). The subBMP + 2µg group showed similar appearance to controls with 
very faint collagen staining except for the periosteum-induced NFB (not shown). SubBMP + 
4µg GST-BGN appeared similar to optBMP in organization (not shown) but higher dose of 
GST-BGN seemed to have slightly more red and compact collagen fibers (4.5E, F). The 
major difference between 4 and 8 μg was the presence of patches of collagen fibers in the 
latter but not in the former. Nonetheless, the use of GST-BGN did not seem to disturb 
collagen organization as did optBMP. 
TRAP 
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Fig 4.7. Immunohistochemistry for phosphorylated Smad 1/5/8 in the rat mandibles. SubBMP (A) and optBMP (B) groups 
show mild to moderate staining for Smad 1/5/8. SubBMP group + 2μg (C), 4μg (D) and 8 μg of GST-BGN (E) show 
modest immunoreactivity. Scale bar on A is 200μm.  
 
When sections were subjected to TRAP-staining to identify osteoclasts, the positive staining 
was observed only in the optBMP group (Fig 4.6A, B). In these sections, the TRAP-positive 
cells were found distributed throughout the NFB in one rat (4.6A) and around the borders of 
the NFB in another (4.6B). All other groups including controls (data not shown), did not 
show any TRAP-positive cells in the observed sections of the NFB area at 2 weeks. Figures 
4.6C and 4.6D show the images of the subBMP+ 4 and 8 µg of GST-BGN groups, 
respectively, showing no TRAP-positive cells.  
Signaling pathways 
p-Smad 1/5/8 signaling was negative for all control groups (not shown). subBMP group 
showed modest staining for p-Smad 1/5/8 (Fig 4.7A) and optBMP group seemed to have 
slightly stronger immunoreactivity (Fig 4,7B). Surprisingly, subBMP + GST-BGN treated 
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Fig 4.8. Immunohistochemistry for phosphorylated (p)-β catenin in the rat mandibles. Absense of immunoreactivity in 
scaffold alone group (A and B). A. Continuous line indicates native bone. B. Middle of defect. C. Moderate 
immunoreactivity for p-β catenin was found within the NFB area of subBMP group. D. Mild to moderate staining of cells 
in the middle region of the defect of subBMP group. E, F.  Strong immunoreactivity for p-β catenin in optBMP. G. 
Moderate immunoreactivity present on subBMP group + 2μg GST-BGN within and around the area of newly formed bone 
(NFB). H. Moderate staining also present in the middle of the defect. Strong  immunostaining for p-β catenin in subBMP 
group + 4 and 8 μg GST-BGN within the NFB (I and K, respectively) as well as in the non mineralized middle of the 
defects (J and L). Scale bar on A is 200μm.  
 
groups showed even less immunoreactivity to p-Smad 1/5/8 compared to subBMP alone (Fig 
4.7C, D and E).  
p-β-catenin showed strong staining in subBMP group (Fig 4.8C, D) compared to 
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controls (represented by scaffold alone, Fig 4.8A, B). The staining was evident around NFB 
(Fig 4.8C) and in the non mineralized area (middle of defect) (Fig 4.8D). OptBMP showed 
much greater intensity of staining for p-β-catenin throughout the NFB (Fig 8E, F). SubBMP 
+ GST-BGN groups all showed strong immunoreactivity (Fig 4.8G-L) but at 4 (4.8I, J) and 8 
µg (4.8K, L) the intensity was more significant within the cells cytoplasm, similar to optBMP 
(4.8E, F). Erk 1/2 did not show positive staining in any of the samples (data not shown). 
 
Discussion 
The generated GST-BGN enhanced BMP-2 signaling and function in vitro as demonstrated 
by Smad 1/5/8 phosphorylation and ALP activity in this study, thus, confirming  our previous 
study [9]. The dose effect was observed up to 4 µg of GST-BGN/150 ng of BMP-2. Potential 
saturation of the ratio of GST-BGN to BMP and/or to receptors may have limited further 
positive effect of GST-BGN on BMP function. Though GST alone did not affect BMP 
function (Fig 1B), with high doses, it could potentially limit the BGN effect by sterically 
impeding the interaction between BMP-2 and its receptors. 
Other pathways besides Smad 1/5/8 as Wnt and Erk 1/2 were not shown to be 
positively influenced by addition of BMP-2 or BMP-2 + GST-BGN after 1h of incubation in 
cell medium. Previously, Wnt/β-catenin pathway has been shown to be activated by BMP-2 
in C2C12, C3H10T1/2 and MC3T3-E1. The increase in ALP activity in those cells were 
found to be due to increases in Wnt proteins like Wnt 3a [20, 21]. The insignificant effect of 
BMP-2 on Wnt signaling in the current study could be due to the passage effect on cells 
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making them produce small amounts of BMPs which would already saturate the Wnt protein 
production.  
In the in vivo study, microcomputed tomography showed that the BV of subBMP + 4 
and 8 µg GST-BGN were similar to that of optBMP (Fig 4.2, lower panel). The optBMP 
group showed a significant amount of bone within the muscle area with limited amount of 
bone bridging the defect. This could be due to the potent osteoinducer effect of this molecule 
on non osteogenic cells (i.e. mesenchymal stem cells). None of the GST-BGN treated groups 
showed this ectopic bone formation. BMP binds to collagen as well as BGN [22-24].  With 
excessive amounts of BMP-2 (optBMP), i.e. 1 µg, it could have led to extravasation of BMP 
to the surrounding tissues leading them to osteoblastic differentiation outside the defect. 
Based on our amino acid analysis, the collagen scaffold used is highly purified collagen 
(hydroxyproline represents ~10% of the total amino acids and glycine ~33% of the total 
amino acids) carrying about 300 µg of collagen in 5mm diameter X 0.5mm thick (Nitta 
Gelatin, Japan). Potentially, a greater amount of collagen per scaffold would have to be used 
to maintain such large amount of BMP-2 in the scaffold, thus, preventing extravasation. 
Nonetheless, GST-BGN in combination with subBMP was a more predictable means of bone 
regeneration than optBMP as the NFB was confined to the defect boundaries. 
OptBMP-treated rats showed bone with higher µCT porosity (53%) than subBMP 
groups treated with 4 and 8 µg of GST-BGN (~25%) and without (30%). Higher porosity 
may be explained by rapid turnover due to increased remodeling spaces and endosteal 
resorption [25, 26]. This notion of high turnover is supported by our finding that osteoclasts 
were identified only in the optBMP groups.  It has been reported that BMP-2 causes a dose- 
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and time-dependent increase in bone resorption pits excavated by highly purified rabbit 
osteoclasts. In this system, it also elevated the mRNA expressions of cathepsin K and 
carbonic anhydrase II, which are key enzymes for the degradation of organic and inorganic 
bone matrices, respectively [27]. Another independent study also showed that in culturing 
osteoblasts in the presence of BMP-2 and inflammatory markers like IL-1, osteoclast-like 
multinucleated cells were formed [28]. Itoh et al., [29] also reported that in mouse bone 
marrow macrophage cultures, BMP-2 also enhanced osteoclast formation in the concomitant 
presence of RANKL.  
The rapid bone turnover seen in the optBMP group is also supported by the pattern of 
PSR staining. Compared to the subBMP treated groups with or without GST-BGN, this 
group exhibited less red and more orange with patches of green color (Fig 4.5C and D). 
When collagen is resorbed and laid down rapidly, the formation of well-aligned, mature 
collagen fibrils could be compromised. In rapid-remodeling tissues, at the molecular level, 
the maturation from divalent to trivalent collagen cross-links is impaired, thus, accumulating 
less stable cross-links   [30, 31].  This can lead to more loosely packed, less stable collagen 
conferring the collagen matrices with orange to greenish color as seen in the optBMP 
histological sections. Rapid turnover of extracellular matrix by BMP-2 has also been 
documented in cartilage. In this study, BMP-2 was overexpressed in healthy murine knee 
joints and proteoglycans synthesis and degradation as well as collagen type I and II mRNA 
expression were investigated. It was found that BMP-2 boosted matrix turnover in intact and 
damaged (IL-1 injected intra-articularly) cartilage [32].  
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Masson’s trichrome staining permitted distinction between the NFB and surrounding 
muscle tissues. The easy distinction between the lamellar native bone and the newly formed 
trabecular bone facilitated quantification of the NFB. The BV measurements by µCT and BA 
by histology were consistent with each other exhibiting that the subBMP + 8 µg of GST-
BGN group showed the greatest BV volume with smaller variation. Previously, it has been 
demonstrated that µCT scans have a high predictive value of the porosity calculated by 
histology. µCT porosity calculations also have showed better estimation of porous structures 
than bone mineral density [11].  
Presence and distribution of BSP was evident in optBMP and all subBMP + GST-
BGN groups. The intense immunoreactivities were found for the optBMP and subBMP + 8 
µg of GST-BGN groups although the distribution was more uniform in the former compared 
to that of the latter. The expression of bone sialoprotein (BSP) is normally restricted to 
mineralizing connective tissues of bones and teeth [33, 34] where it has been associated with 
mineral crystal formation [35]. The fact that BSP was deposited in a location distant from 
mineralized areas within the defect could indicate those areas would be mineralized soon. 
Smad signaling has been well recognized as the canonical pathway upon BMP-2 
transduction through BMP receptors [36, 37]. With high dose of BMP-2 (optBMP), some 
increase in immunoreactivity for phosphorylated Smad 1/5/8 was noticed compared to the 
subBMP group. However, although our in vitro studies and others [8, 9, 38] have shown that 
BGN significantly increases Smad 1/5/8 signaling, this was not observed in vivo. It is 
important to note that this signaling is representative of the mechanism of in vivo 
osteogenesis at 2 weeks post surgery. Early signaling in vivo of the BGN assisted BMP-
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induced osteogenesis has not been investigated. It is clear that at 2 weeks though, 
phosphorylation of β-catenin was occurring very strongly within the NFB in subBMP, 
optBMP and subBMP + GST-BGN treated samples. Except for subBMP, the degree of 
phosphorylation was similar and indicates that at least in part the osteogenesis is occurring 
through activation of Wnt signaling. In the non-mineralized areas GST-BGN treated groups, 
p-β-catenin was also highly stained compared to control or subBMP. Wnt signaling has been 
associated with in vivo bone regeneration in rats and mice. BMP-2 up-regulates expression of 
several Wnt ligands and their receptors. Mice expressing conditional β-catenin null alleles 
displayed an inhibition of BMP-induced osteogenesis [39]. It has also been suggested that at 
later stages of repair, when cells have already been committed to mesenchymal lineage, β-
catenin is specifically upregulated and the main pathway in bone regeneration [40]. The data 
suggest that the BGN-assisted osteogenesis could be due in part to this pathway.  Through 
upregulation of BMP-2 signaling, GST-BGN positively affects Wnt signaling leading to 
increased osteogenesis. Like in vitro, there was no activation of ERK 1/2 pathways found for 
BMP-2 or BGN-assisted BMP-2 function in vivo. 
In summary, this study demonstrated that: 1. BGN core protein specifically and 
predictably enhances BMP-2 function in vitro and in vivo, 2. The bone formed by a favorable 
ratio of a low dose of BMP-2 to GST-BGN have similar volume, less porosity and more 
organization and maturity than those formed by a high dose of BMP-2 at 2 weeks post-
surgery, and 3. Wnt signaling is strongly activated by BMP-2 and BGN-assisted BMP-2 
osteogenesis in vivo at 2 weeks post-surgery. This study provides additional evidence that 
BGN core protein could be predictably used in clinical settings to enhance BMP-2 induced 
bone formation.  
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Abstract 
We have found that BGN core is responsible for the positive effect on BMP-2 function while 
the glycosaminoglycan component rather functions as a suppressor for this effect. In this 
study, we explored the effects of various domains of BGN core protein [central leucine-rich 
repeat (LRR) domains with deleted N and C terminal cysteine loops (ΔNC), N terminal to 
LRR) 6 (N~LRR6), LRR7 to C terminal (LRR7~C) and LRRs 1 to 3 (LRR1~3), 4 to 6 
(LRR4~6) and 7 to 10 (LRR7~10)] on BMP-2 function. Methods: The glutathione-S-
transferase (GST) tagged deletion constructs were generated in E. coli system by deletion of 
the specific BGN core domains as described above. After purification, 4 µg of each construct 
was added to C2C12 cells in combination with 150 ng of BMP-2. After cell lysis, lysates 
were subjected to p-Smad 1/5/8 Western Blot and ALP activity assay. The construct found 
most effective for BMP-2 function was further tested on the rat mandible model (see Study I 
and II) with a suboptimal dose of BMP-2 (subBMP/100 ng). Results: Smad 1/5/8 
phosphorylation was the greatest with N~LRR6 and ALP activity was significantly enhanced 
with the constructs ΔNC, N~LRR6 and LRR1~3. Thus, LRR1~3 was further tested in vivo. 
In the animal experiments, LRR1~3 showed significant bone regeneration capacity when 
combined with subBMP and the enhancement was comparable to that of (subBMP + GST-
BGN). Conclusion: The positive modulation of BMP-2 function by BGN or its functional 
domains occurs through Smad 1/5/8 leading to an increase in ALP activity in C2C12 cells. 
The effector domain appears to reside between the N terminus and LRR6, possibly in the 
LRR1~3, and it is effective in promoting BMP-2 induced osteogenesis in vivo. 
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Introduction 
BGN has been increasingly investigated in the past decade for its function in modulation of 
BMP functions [1-5]. The BGN knock out study was the first to show the effect of this 
proteoglycan on bone homeostasis demonstrating that the null mice had age-dependent 
osteoporosis [6]. The same group later reported that without BGN, calvaria cells responded 
poorly to BMP-4 [1, 7]. Independent of this study, our laboratory has also reported that BGN 
is a positive modulator of osteoblastic function and it promotes matrix mineralization [2]. In 
vivo, we have shown that BGN facilitates bone formation without compromising matrix 
organization [2] (also see Chapter 4, Study II). One of our recent findings was that the core 
protein of BGN, not its glycosaminoglycans, is responsible for this positive effect on BMP 
functions [5] (also see Chapter 3, Study I). BGN is composed of 10 leucine rich repeats 
(LRR) flanked by two cysteine-rich domains, a characteristic that has been known to promote 
protein-protein interactions [8, 9]. Among the core polypeptide sequence in BGN, there is no 
peculiarity in the LRRs described in the literature that would seem to favor more protein-
protein interactions. However, the key may reside in the position of certain amino acid(s) in 
the peptide sequence turns or pockets (i.e. secondary structure) that could favor interaction 
with BMP-2 and/or its receptors. For example, it has been reported that while phenylalanine 
85 in a pocket of the BMP type I receptor (ALK3) is essentical for the interaction between 
BMP-2 and this receptor, for more efficient interaction, the conformation involving non 
consecutive 27 residues from ALK3 and 26 from BMP-2 are required [10].  
In this study, we attempted to establish which domain of the BGN core protein is 
responsible for the positive effect on BMP function. For this purpose, we generated several 
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Table 1. Primers for generation of GST-BGN and GST-deletion constructs. 
BGN deletion constructs and evaluated the effects of these domains on BMP-2 function in a 
C2C12 cell assay system [11]. In addition, we selected the smallest functional domain and 
applied to a rat mandible model [12] and investigated early bone regeneration.  
  
Experimental Procedures 
Generation of recombinant full BGN and BGN deletion constructs 
Generation of full glutathione-S-transferase (GST) tagged BGN was described earlier in 
Mochida et al., 2006 [3]. To investigate the effects of the N, C termini (i.e. cysteine rich 
domains) and LRR domains of BGN on BMP-2 function in vitro we generated the following 
BGN-derived constructs: LRRs with deleted N and C termini (ΔNC), N-terminus to LRR 6, 
(N~LRR6), LRR7 to C-terminus (LRR7~C), and several LRR domains: LRR1~3, LRR4~6 
and LRR7~10 (Fig 5.1). A total of 6 deletion constructs were generated with described 
primers (Table 1).  
          Primers                   
 
Forward Reverse 
BGN see Mochida et al., 2006 see Mochida et al., 2006 
ΔNC 5’GCGGATCCACACTGCTAGACCTG3’ 5’GCCTCGAGGGTGATGTTGTT3’ 
N~LRR6 same as BGN, see Mochida et al., 2006 5’GCCTCGAGAGTGTGGCCTCTGA-3’ 
LRR7~C 5’GCGGATCCACCCTGAACGAACTT3’ same as BGN, see Mochida et al., 2006 
LRR1~3 5’GCGGATCCACACTGCTAGACCTG3’ 5’GCCTCGAGCACCAGCAGGGCTAG3’ 
LRR4~6 5’GCGGATCCTCCCTGGTAGAACTA3’ 5’GCCTCGAGAGTGTGGCCTCTGA3’ 
LRR7~10 5’GCGGATCCACCCTGAACGAACTT3’ 5’GCCTCGAGGGTGATGTTGTT3’ 
GST-
construct 
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Fig 5.1.Drawing scheme of BGN core protein (upper panel) and deletion constructs (lower panel). BGN: biglycan, LRR: 
leucine rich repeat, ΔNC: LRR one to ten without N and C terminal, N~LRR6: N terminal to LRR6, LRR7~C: LRR7 to C 
terminal, LRR1-3: LRR one to three, LRR4-6: four to six, LRR7-10: seven to ten. C: cysteine. Wavy boxes: random amino 
acids between cysteine clusters. Numbered boxes: LRRs. 
 
 
 The amplified PCR products were then digested by restriction enzymes, ligated into 
pGEX4T-1 vectors (Amersham Biosciences, Piscataway, NJ), sequenced and the plasmids 
harboring the mutant Bgn cDNAs (pGEX4T-1-Bgn constructs) were obtained. The plasmids 
were transformed into BL21-CodonPlus bacterial strain, the synthesis of GST-BGN fusion 
protein was induced by isopropyl -D-1-thiogalactopyranoside (IPTG, Fisher Scientific, 
Waltham, MA) and the GST-deletion constructs/proteins were purified in the same manner 
as described [3]. Additionally, purification was carried out by molecular sieve 
chromatography using a Superdex 200 (HiLoad 16/60, GE Healthcare, Waukesha, WI) 
column in  2M guanidine-HCl, pH 7.5, for ΔNC, N~LRR6 and LRR7~C.  The purified 
fractions were dialyzed against distilled water for 3 days to remove the salt and lyophilized. 
Then GST-fused BGN-derived constructs were subjected to SDS-PAGE and WB analysis 
with anti-GST antibody (Sigma-Aldrich, St. Louis, MO). Quantification of proteins after 
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purification was carried out by the Lowry method [13] with the DC protein assay kit (Bio-
rad). 
Cell line and culture conditions 
C2C12 cells were cultured as previously described [3], and in Chapter 3, Study I and Chapter 
4, Study II.  
Effect of BGN and BGN-derived constructs on BMP-2 function in vitro 
The effect of recombinant BGN and deletion constructs on canonical BMP-2 pathway was 
assessed by  Smad1/5/8 phosphorylation in C2C12 cells as described in Chapter 3, Study I 
[5] and Chapter 4, Study II. Four µg of BGN or BGN deletion constructs were added in 
combination with 150 ng of BMP-2 to the cell medium. Cell extracts were then applied to 4-
12% SDS-PAGE followed by WB analyses with anti-phospho (p)-Smad1/5/8 (Cell 
Signaling, Danvers, MA) and anti-β actin antibody (Cell Signaling).  These experiments were 
repeated in duplicates. 
For ALP activity, after 3 days of culture in the above conditions, the cell lysates were 
collected and subjected to microplate reading at an absorbance of 405nm after 15 minutes as 
reported [3]. ALP assay was performed in duplicate. 
 
Effect of short most beneficial BGN domain on BMP-2 function in vitro on in vivo 
osteogenesis  
After the in vitro investigations described above, the LRR1~3 construct that revealed the 
greatest effect on BMP-2 function among the three short LRR constructs (i.e. LRR1~3, 4~6 
90 
 
 
Fig 5.2. Generation of GST-tagged BGN deletion constructs and verification of purification by SDS-PAGE and WB 
(anti-GST). A. Commassie brilliant blue staining (CBB) of 4-12% gel showing ΔNC (63 kDa)(lane 1), N~LRR6 (46 
kDa) (lane 2), LRR7~C (42 kDa)(lane 3). WB for ΔNC (lane 4), N~LRR6 (lane 5) and LRR7~C (lane 6). B. Purified 
LRR1~3 (33 kDa)(lanes 1 and 4),  LRR4~6 (33.4 kDa)(lanes 2 and 5), LRR7~10 (36.5 kDa)(lanes 3 and 6) shown in 
SDS-PAGE by CBB and WB by anti-GST. Note that purity of LRR4~6 is the most compromised with several bands 
other than the band of interest. Arrows indicate bands of interest. 
 
and 7~10) was tested in vivo. The effect and specificity were tested by applying three doses 
in combination with a suboptimal dose of BMP-2 (subBMP/100ng) (see Chapter 4, Study II). 
The rat mandible model and the surgical procedures have been described in Chapter 3, Study 
I [5]. The rats (2 per group) included in this study were as reported for Chapter 4, Study II for 
controls (i.e. unfilled, scaffold, scaffold + GST, scaffold + GST-BGN) and for treatment 
groups (scaffold + subBMP or subBMP + GST-BGN). In addition, the following treatment 
groups were investigated: subBMP + 4,  8 and 16 µg GST-LRR1~3. At 2 weeks post-
surgery, hemimandibles were placed in neutral buffered formalin and after three days they 
were evaluated by μCT. The procedures were described in Chapter 3, Study I [5] and the BV 
and porosity calculated as in Chapter 4, Study II. 
Results 
Generation of constructs and verification of signaling pathways and ALP activity  
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Fig 5.3. Effect of BGN deletion constructs on BMP-2 function in C2C12 cells A. Smad 1/5/8 phosphorylation in 
C2C12 cells treated with BMP-2 alone (lane 2) or with addition of GST-BGN (lane 3) and BGN deletion constructs 
(lanes 4-6). Note that GST-BGN significantly increases phosphorylation (lane 3) but the effect is much greater for 
N~LRR6 (lane 5). B. ALP activity  of cells treated with BMP-2 (lane 2) is significantly increased by the addition of 
GST-BGN (lane 3) but the effect is further enhanced by ΔNC (lane 4), N~LRR6 (lane 5) and LRR1~3 (lane 7). 
Greatest ALP values highlighted by red boxes. Figures are representatives of duplicate experiments. 
 
Constructs were generated successfully with various levels of purity. The larger constructs 
ΔNC, N~LRR6 and LRR7~C (Fig 5.2A lane 1, 2 and 3 respectively) were further purified by 
molecular sieve chromatography but ΔNC still contained some other peptides that could not 
be separated (Fig 5.2A, lane 1). The WB analysis with anti-GST antibody indicated that the 
other peptides did not contain GST (Fig 5.2A, lane 4). LRR constructs were relatively pure 
(Fig 5.2B) with exception of LRR1~4 (lanes 2 and 5). In Fig 5.3, Smad 1/5/8 
phosphorylation was significantly enhanced when GST-BGN was added to BMP-2 (Fig 
5.3A, lane 3). ΔNC and LRR7~C also enhanced BMP-2 induced Smad phosphorylation 
(lanes 5 and 6, respectively) but when N~LRR6 was added to BMP-2, the signaling was the 
greatest (lane 4). Fig 5.3B shows a representative graph of ALP activity where the deletion 
constructs ΔNC (lane 4), N~LRR6 (lane 5) and LRR1~3 (lane 7) were the most effective 
constructs to enhance the BMP-2 function (all highlighted by red boxes). N~LRR6 exhibited 
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Fig. 5.4. μCT 2D and 3D views and BV quantification of NFB in the rat mandibles treated with BMP-2 and BGN deletion 
construct  LRR1~3. Refer to Chapter 4, study II for data on controls (unfilled, scaffold alone, scaffold + GST, scaffold + 
GST-BGN) and treatment groups for comparison (subBMP and subBMP+ GST-BGN). Upper panel on the left shows 3D 
view and lower panel 2D view. On the right, bone volume (BV) was quantified as previously described (see Chapters 3 
and 4). Graph shows the median (represented by columns) and the range (error bars) of BV of the newly formed bone 
(NFB) of 2 defects per group of treatment. Total defect is 9.8 mm3Note that the lowest dose of LRR1~3 enhances BMP-2-
induced osteogenesis the most (lane 2). subBMP:  suboptimal dose of BMP-2 (100 ng), LRR1~3: leucine rich repeat one to 
three.  
 
~3.5 fold increase in ALP compared to BMP-2 alone. ΔNC and LRR1~3 were more than 2 
fold increased than BMP-2 alone. Other groups a LRR7~C and LRR4~6 (lanes 5 and 7, 
respectively) showed some increases in ALP compared to that of BMP-2 alone but still lower 
than (BMP-2 + GST-BGN) (lane 3).  
μCT analyses 
Figure 5.4 shows the representative 3D and 2D µCT images obtained after euthanasia at 2 
weeks post-surgery. Right graph shows quantification of bone volume (BV). In Study I and II 
we described the findings for empty, scaffold alone, scaffold + GST, scaffold + GST-BGN 
alone control groups and for subBMP and (subBMP + GST-BGN) treatment group. The BV 
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of the treatment group subBMP is shown again as a reference (lane 1). When subBMP was 
combined with 4 and 8µg of GST-LRR1~3, a remarkable increase in bone formation was 
achieved compared to subBMP alone (lane 2 and 3, respectively). Like previously 
demonstrated for GST-BGN (see Study II), the bone was confined to the defect area and not 
ectopic (see optBMP/1μg in Study II). The amount of bone regenerated diminished with 
increasing doses of GST-LRR1~3 (lanes 2, 3 and 4). Porosity calculated by the µCT software 
CTan Analyzer (Skyscan, Kontich, Belgium) within the newly formed bone (NFB) 
boundaries showed that subBMP and optBMP groups had 30% and 53% porosity (reported 
in Study II), respectively. The (subBMP + GST-BGN) groups showed similar porosity for all 
groups averaging 25% and for GST-LRR1~3 was about 30%. 
 
Discussion 
In this study we explored the effectiveness of BGN-derived domains on BMP-2 function. 
The results indicated that the central LRR domain (i.e. no N and C-terminal cysteine rich 
domains) alone can facilitate BMP-2 function as evidenced by the positive effect on Smad 
phosphorylation and ALP activity. When the shorter LRR sequences were tested separately, 
LRR1~3 showed the greatest effect followed by LRR4~6 (Fig 5.3). The LRR7~10 exerted no 
significant effect. However, due to the presence of other peptides in the LRR4~6 construct 
(Fig 5.2), the effect of this construct could have been affected. This construct had many non-
determined, GST-tagged contaminants. Further purification was attempted by molecular 
sieve chromatography without success. It is possible that since contaminants were GST-
tagged, aggregation occurred even in the presence of chaotropic agent such as guanidine-
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HCl. Also, the close molecular weight of the contaminants to the protein of interest could 
make separation difficult. 
The effect of LRR1~3 addition to subBMP on osteogenesis in vivo was remarkable as 
was seen for GST-BGN (see Chapter 3, Study II). However, the higher the dose of LRR1~3 
the smaller the positive effect on BMP-2-induced osteogenesis. Before drawing conclusions 
from this negative effect with increasing doses of GST-LRR1~3 it would be ideal to test tag-
free LRR1~3. This leucine rich amino acid stretch is only 68 amino acids long while its tag, 
GST, contains  226 amino acids. Though GST alone did not affect the BMP-2 function in 
vivo (Chapter 4, Study II) with higher concentrations, it may hinder the interaction of such a 
small domain with BMP-2 or receptors. In addition, the use of GST-tag significantly changes 
the isoelectric point (pI) of LRR1~3 from 7.6 to 10 but in case of BGN the pI only changes 
from 7.8 to 8.  This could also change protein-protein interactions. In the future, we will 
generate small LRR sequences free of tags by using chemically synthesized peptides. 
The newly formed bone of (subBMP + LRR1~3) treated hemimandibles had similar 
porosity to that of the (subBMP + GST-BGN) which was lower than the mandibles treated 
with an optimal dose of BMP-2 (optBMP) (see Chapter 4, study II). Reduced porosity is 
usually associated with lower bone turnover and high bone density. Lower bone turnover has 
been  shown to confer bone better mechanical properties [14, 15]. It will be interesting to 
investigate how the bone remodels and ultimately fills the defect by the treatments with 
(subBMP + BGN), (subBMP + BGN domain) or optBMP after a longer period of time.  
There may be more than one mechanism by which BGN assists BMP function. Not 
only through LRRs but possibly through the C terminal cysteine rich domain as well since 
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there is still some enhancement of BMP function with LRR7~C but not with LRR7~10. 
Previously, we have found that the cysteine cluster of the C terminus in BGN is necessary for 
BGN binding to ALK6 receptor (not published). Thus, the C terminus of LRR7~C may help 
BMP-2 function through ALK6 while LRRs (i.e. 1~3 and possibly 4~6) alone may utilize 
BMP-2 or other receptor(s) interaction. Nonetheless, use of the most effective domain 
combined with low concentrations of BMP-2 appears to be a more predictable, controllable 
and cost effective approach than the current marketed high dose BMP-2 delivery. 
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Chapter 6 
Conclusions 
 
1. BGN is a positive modulator of BMP-2 function in vitro in C2C12 cells and removal 
of GAGs further enhances BGN assistance of BMP function 
2. Tissue extracted BGN (glycanated BGN, with GAGs) is not able to positively 
modulate BMP function in vivo in a critical-sized rat mandible defect model 
3. Recombinant BGN core protein (without GAGs) is efficient in positively modulating 
BMP-2 function in vitro and in vivo as determined by the C2C12 system and the rat 
mandible model 
4. Smad 1/5/8 is the main pathway of BGN-assisted BMP-2 function in C2C12 cells 
5. The BGN core + a suboptimal dose of BMP-2 induced newly formed bone (NFB) 
that was similar in bone volume but less porous, more compact and organized than 
the NFB by an optimal dose of BMP-2 
6. The NFB of BGN core + a suboptimal dose of BMP showed a strong β-catenin 
immunostaining, similar to optimal dose of BMP-2.  
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7. The effector domain of the core of BGN may reside in the N-terminal through leucine 
rich repeat (LRR)~6 based on Smad signaling and ALP activity. LRR1~3 is likely the 
effector domain. 
